System for treating embolism and associated devices and methods

Description

TECHNICAL FIELD

The present technology relates generally to systems, methods, and devices for the intravascular treatment of emboli and/or thrombi within a blood vessel of a human patient. In particular, some embodiments of the present technology relate to systems for releasing stored vacuum pressure to aspirate clot material from a blood vessel.

BACKGROUND

Thromboembolic events are characterized by an occlusion of a blood vessel. Thromboembolic disorders, such as stroke, pulmonary embolism, heart attack, peripheral thrombosis, atherosclerosis, and the like, affect many people. These disorders are a major cause of morbidity and mortality.

When an artery is occluded by a clot, tissue ischemia develops. The ischemia will progress to tissue infarction if the occlusion persists. However, infarction does not develop or is greatly limited if the flow of blood is reestablished rapidly. Failure to reestablish blood flow can accordingly lead to the loss of limb, angina pectoris, myocardial infarction, stroke, or even death.

In the venous circulation, occlusive material can also cause serious harm. Blood clots can develop in the large veins of the legs and pelvis, a common condition known as deep venous thrombosis (DVT). DVT commonly occurs where there is a propensity for stagnated blood (e.g., long distance air travel, immobility, etc.) and clotting (e.g., cancer, recent surgery, such as orthopedic surgery, etc.). DVT can obstruct drainage of venous blood from the legs leading to swelling, ulcers, pain and infection. DVT can also create a reservoir in which blood clots can collect and then travel to other parts of the body including the heart, lungs, brain (stroke), abdominal organs, and/or extremities.

In the pulmonary circulation, the undesirable material can cause harm by obstructing pulmonary arteries—a condition known as pulmonary embolism. If the obstruction is upstream, in the main or large branch pulmonary arteries, it can severely compromise total blood flow within the lungs, and therefore the entire body. This can result in low blood pressure and shock. If the obstruction is downstream, in large to medium pulmonary artery branches, it can prevent a significant portion of the lung from participating in the exchange of gases to the blood resulting in low blood oxygen and buildup of blood carbon dioxide.

There are many existing techniques to reestablish blood flow through an occluded vessel. Embolectomies, for example, are a surgical technique involving incising a blood vessel and placing a balloon-tipped device (such as the Fogarty catheter) at the location of the occlusion. The balloon is then inflated at a point beyond the clot and used to withdraw the obstructing material back to the point of incision. The obstructing material is then removed by the surgeon. Although such surgical techniques have been useful, exposing a patient to surgery may be traumatic and best avoided when possible. Additionally, the use of a Fogarty catheter may be problematic due to the possible risk of damaging the interior lining of the vessel as the catheter is being withdrawn.

Percutaneous methods are also utilized for reestablishing blood flow. A common percutaneous technique is referred to as balloon angioplasty where a balloon-tipped catheter is introduced to a blood vessel (e.g., typically through an introducing catheter). The balloon-tipped catheter is then advanced to the point of the occlusion and inflated to dilate the stenosis. Balloon angioplasty is appropriate for treating vessel stenosis, but it is generally not effective for treating acute thromboembolisms as none of the occlusive material is removed and restenosis regularly occurs after dilation. Another percutaneous technique involves placing a catheter near the clot and infusing streptokinase, urokinase, or other thrombolytic agents to dissolve the clot. Unfortunately, thrombolysis typically takes hours to days to be successful. Additionally, thrombolytic agents can cause hemorrhage, and in many patients the thrombolytic agents cannot be used at all.

Various devices exist for performing a thrombectomy or removing other foreign material. However, such devices have been found to have structures which are either highly complex, cause trauma to the treatment vessel, or lack the ability to be appropriately fixed against the vessel. Furthermore, many of the devices have highly complex structures that lead to manufacturing and quality control difficulties as well as delivery issues when passing through tortuous or small diameter catheters. Less complex devices may allow the user to pull through the clot, particularly with inexperienced users, and such devices may not completely capture and/or collect all of the clot material.

Thus, there exists a need for improved systems and methods for embolic extraction.

BRIEF DESCRIPTION OF THE DRAWINGS

Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present disclosure.

FIG. 1 is a partially schematic side view of a clot removal system configured in accordance with the present technology.

FIG. 2 is a side view of a locking syringe configured in accordance with the present technology.

FIG. 3A is a side view of a locking syringe configured in accordance with the present technology.

FIG. 3B is a side view of an adaptor for connecting the locking syringe of FIG. 3A to the clot removal system of FIG. 1 configured in accordance with the present technology.

FIG. 3C is a side view of the adaptor of FIG. 3B coupled to the locking syringe of FIG. 3A.

FIG. 3D is a side view of the locking syringe of FIG. 3A coupled to the clot removal system of FIG. 1 via the adaptor of FIG. 3B.

FIG. 4A is a perspective side view of another pressure source configured in accordance with the present technology, and FIGS. 4B and 4C are enlarged schematic side views of the pressure source of FIG. 4A during operation.

FIG. 5 is a cross-sectional side view of an automatic release syringe configured in accordance with the present technology.

FIG. 6 is a perspective top view of a syringe configured in accordance with the present technology.

FIG. 7 is a side view of an over-wire locking syringe configured in accordance with the present technology.

FIG. 8 is a flow diagram of a process or method for operating a clot removal system in accordance with the present technology.

FIGS. 9A-9C are side views of a proximal portion of the clot removal system of FIG. 1 during a clot removal procedure using the locking syringe of FIG. 3 in accordance with the present technology.

FIGS. 10A and 10B are schematic illustrations of a distal portion of the clot removal system of FIG. 1 during a clot removal procedure in accordance with the present technology.

FIG. 11 is a partially schematic side view of another clot removal system configured in accordance with the present technology.

FIG. 12 is a flow diagram of another process or method for operating a clot removal system in accordance with the present technology.

FIGS. 13A-14C are schematic illustrations of a distal portion of the clot removal system of FIG. 11 during a clot removal procedure in accordance with the present technology.

FIG. 15 is a flow diagram of another process or method for operating a clot removal system in accordance with the present technology.

FIGS. 16A-16E are schematic illustrations of a distal portion of the clot removal system of FIG. 11 during a clot removal procedure in accordance with the present technology.

FIG. 17 is a partially schematic side view of another clot removal system configured in accordance with the present technology.

FIGS. 18A-18H are side views of a distal portion of the clot removal system shown of FIG. 17 during a clot removal procedure in accordance with the present technology.

FIG. 19 is a perspective side view of a pressure source for filtering blood from aspirated clot material during a clot removal procedure configured in accordance with the present technology.

FIG. 20A is a partially-exploded side view of a filter device and pressure source configured in accordance with the present technology.

FIG. 20B is a perspective side view of the syringe of FIG. 20A coupled to the filter device of the FIG. 20A.

FIG. 20C is a side view of the filter device and syringe of FIG. 20B coupled to the clot removal system of FIG. 1.

FIGS. 20D and 20E are side views of the syringe of FIG. 20A coupled to the clot removal system of FIG. 1 for reintroducing blood to a patient.

FIG. 21A is a partially-exploded side view of a filter device, a pressure source, and a reinfusion syringe configured in accordance with the present technology.

FIG. 21B is a perspective side view of the filter device of FIG. 21A coupled to the pressure source and the reinfusion syringe of FIG. 21A.

FIG. 22 is a partially-exploded side view of a filter device configured in accordance with the present technology.

FIG. 23 is a partially-exploded side view of a filter device configured in accordance with the present technology.

FIG. 24 is an enlarged isometric view of the clot removal system of FIG. 1 configured in accordance with the present technology.

FIG. 25 is an enlarged isometric view of the clot removal system of FIG. 1 configured in accordance with the present technology.

DETAILED DESCRIPTION

The present technology is generally directed to methods and systems for removing clot material from a blood vessel of a human patient. In some embodiments, a catheter can be intravascularly positioned within a blood vessel such that a distal portion (e.g., a distal opening) of the catheter is positioned proximate to clot material within the blood vessel. The catheter can be fluidly coupled to a pressure source via a valve or other fluid control device positioned outside of the patient. With the valve closed, the pressure source can be activated to charge a vacuum chamber of the pressure source with a vacuum. The valve can then be opened to apply the vacuum to the catheter to thereby aspirate at least a portion of the clot material from the blood vessel into the catheter. In some embodiments, an interventional device can be delivered through the catheter and used to engage the clot material before and/or after the vacuum is applied to the catheter.

In one aspect of the present technology, the pressure source is configured to generate a vacuum and store the vacuum before the pressure source is fluidly connected to the catheter. Therefore, opening the fluid control device can instantaneously or nearly instantaneously apply the stored vacuum pressure to the catheter, thereby generating suction throughout the catheter. In particular, the suction is applied at the distal portion of the catheter proximate to the clot material. Pre-charging or storing the vacuum before applying the vacuum to the catheter can generate greater suction forces (and corresponding fluid flow velocities) at and/or near the distal portion of the catheter compared to, for example, simply activating the pressure source while it is fluidly connected to the catheter. The greater suction forces generated by application of the stored vacuum can be used to aspirate or otherwise remove clot material from within a blood vessel of a human patient.

Although many of the embodiments are described below with respect to devices, systems, and methods for treating a pulmonary embolism, other applications and other embodiments in addition to those described herein are within the scope of the technology (e.g., intravascular procedures other than the treatment of emboli, intravascular procedures for treating cerebral embolism, intravascular procedures for treating deep vein thrombosis (DVT), etc.). Additionally, several other embodiments of the technology can have different configurations, states, components, or procedures than those described herein. Moreover, it will be appreciated that specific elements, substructures, advantages, uses, and/or other features of the embodiments described with reference to FIGS. 1-25 can be suitably interchanged, substituted or otherwise configured with one another in accordance with additional embodiments of the present technology. Furthermore, suitable elements of the embodiments described with reference to FIGS. 1-25 can be used as standalone and/or self-contained devices. A person of ordinary skill in the art, therefore, will accordingly understand that the technology can have other embodiments with additional elements, or the technology can have other embodiments without several of the features shown and described below with reference to FIGS. 1-25.

With regard to the terms “distal” and “proximal” within this description, unless otherwise specified, the terms can reference a relative position of the portions of a catheter subsystem with reference to an operator and/or a location in the vasculature. Also, as used herein, the designations “rearward,” “forward,” “upward,” “downward,” etc. are not meant to limit the referenced component to use in a specific orientation. It will be appreciated that such designations refer to the orientation of the referenced component as illustrated in the Figures; the systems of the present technology can be used in any orientation suitable to the user.

The headings provided herein are for convenience only and should not be construed as limiting the subject matter disclosed.

I. Selected Embodiments of Clot Removal Systems

FIG. 1 is a partially schematic side view of a clot treatment or clot removal system comprising an aspiration assembly 10 (“assembly 10”) configured in accordance with an embodiment of the present technology. In the illustrated embodiment, the assembly 10 includes a catheter subsystem 100, a tubing subsystem 120, and a pressure source 140. The catheter subsystem 100 includes a catheter 102 (e.g., an aspiration catheter) comprising an elongated shaft defining a lumen 104 and having a distal portion 103a and a proximal portion 103b. The catheter subsystem 100 further includes a valve 106 that can be integral with or coupled to the proximal portion 103b of the catheter 102.

In the illustrated embodiment, the valve 106 includes a distal portion 107a, a proximal portion 107b, and a lumen 109 extending therethrough from the distal portion 107a to the proximal portion 107b. The valve 106 further includes a flow controller (obscured in FIG. 1) in the lumen 109. In some embodiments, the valve is a hemostasis valve that is configured to maintain hemostasis during a clot removal procedure by preventing fluid flow in the proximal direction through the valve 106 as various components such as delivery sheaths, pull members, guidewires, interventional devices, other aspiration catheters (e.g., as described in detail with reference to FIGS. 11-16E), etc., are inserted through the valve 106 to be delivered through the catheter 102 to a treatment site in a blood vessel. The valve 106 further includes a branch or side port 108 positioned distally of the flow controller in the lumen 109 and configured to fluidly couple the lumen 104 of the catheter 102 to the tubing subsystem 120. In the illustrated embodiment, the valve 106 includes buttons 101 that can be actuated (e.g., depressed) to open a conduit within the lumen 109. In some embodiments, the valve 106 can be a valve of the type disclosed in U.S. patent application Ser. No. 16/117,519, filed Aug. 30, 2018, and titled “HEMOSTASIS VALVES AND METHODS OF USE,” which is incorporated herein by reference in its entirety. In some embodiments, the proximal portion 107b of the valve 106 is further configured to be detachably coupled (e.g., via a snap-fit arrangement) to a retraction/aspiration device for aspirating the lumen 104 of the catheter 102 and/or for retracting an interventional device, catheter, delivery sheath, catheter, etc., positioned within the lumen 104. Specific details of such retraction/aspiration devices and associated methods are disclosed in U.S. Pat. No. 9,526,864, filed Jun. 9, 2015, and titled “RETRACTION AND ASPIRATION DEVICE FOR TREATING EMBOLISM AND ASSOCIATED SYSTEMS AND METHODS,” which is incorporated herein by reference in its entirety.

The tubing subsystem 120 fluidly couples the catheter subsystem 100 to the pressure source 140. More specifically, the tubing subsystem 120 can include one or more tubing sections 124 (individually labeled as a first tubing section 124a and a second tubing section 124b), at least one fluid control device 126 (e.g., a valve), and at least one connector 128 for fluidly coupling the tubing subsystem 120 to the pressure source 140 and/or other suitable components. More specifically, in the illustrated embodiment, the fluid control device 126 is a stopcock that is fluidly coupled to (i) the side port 108 of the valve 106 via the first tubing section 124a and (ii) the connector 128 via the second tubing section 124b. In some embodiments, the fluid control device 126 can define a lumen having a diameter (or other cross-sectional dimension) that is greater than or equal to a diameter of the lumen 104 of the catheter 102, a diameter of the first tubing section 124a, and/or a diameter of the second tubing section 124b.

The fluid control device 126 is externally operable by a user to regulate the flow of fluid therethrough and, specifically, from the lumen 104 of the catheter 102 to the pressure source 140. In other embodiments, the fluid control device 126 can be a clamp that can be actuated (e.g., compressed or squeezed by the hand of a user) to partially or fully restrict fluid flow through the tubing section 124a and/or the tubing section 124b. In yet other embodiments, the fluid control device 126 can be omitted and its functionality incorporated into the pressure source 140 (e.g., as described in detail below with reference to FIG. 5). In some embodiments, the fluid control device 126 can include a quick-release mechanism (e.g., a spring-loaded apparatus) for rapidly opening, unclamping, etc., the fluid control device 126 to (e.g., instantaneously or nearly instantaneously) fluidly connect the pressure source 140 and the catheter 102. In some embodiments, the fluid control device 126 can be opened/closed automatically (e.g., by a motor, switch, etc.). When the pressure source 140 is pre-charged with a vacuum, as described in detail below, such a quick-release fluid control device 126 can reduce the time needed for pressure in the assembly 10 to equalize after opening of the fluid control device 126, and can thereby increase suction forces generated at the distal portion 103a of the catheter 102.

In some embodiments, the connector 128 is a quick-release connector (e.g., a quick disconnect fitting) that enables rapid coupling/decoupling of the catheter 102 and the fluid control device 126 to/from the pressure source 140. In other embodiments, the tubing subsystem 120 can have more or fewer tubing sections, connectors, and/or fluid control devices, and can have other suitable configurations. In some embodiments, one or more of the components can be permanently connected and/or integrally formed.

The pressure source 140 is configured to generate (e.g., form, create, charge, build-up, etc.) a vacuum (e.g., negative relative pressure) and store the vacuum for subsequent application to the catheter subsystem 100. Further details of suitable pressure sources are described in detail below with reference to FIGS. 2-7. During operation of the assembly 10, a user can first close the fluid control device 126 before activating the pressure source 140 to build up vacuum pressure within the pressure source 140 (e.g., a vacuum chamber of the pressure source 140). In some embodiments, the user can control or select the volume of the generated vacuum. In this manner, a vacuum is charged within the pressure source 140 before the pressure source 140 is fluidly connected to the catheter subsystem 100. To aspirate the lumen 104 of the catheter 102, the user can open the fluid control device 126 to fluidly connect the pressure source 140 to the catheter subsystem 100 and thereby apply or release the vacuum stored in the pressure source 140 to the lumen 104 of the catheter 102. Opening of the fluid control device 126 instantaneously or nearly instantaneously applies the stored vacuum pressure to the tubing subsystem 120 and the catheter 102, thereby generating suction throughout the catheter 102. In particular, the suction is applied at the distal portion 103a of the catheter 102. In one aspect of the present technology, pre-charging or storing the vacuum before applying the vacuum to the lumen 104 of the catheter 102 is expected to generate greater suction forces (and corresponding fluid flow velocities) at and/or near the distal portion 103a of the catheter 102 compared to simply activating the pressure source 140 while it is fluidly connected to the catheter 102. As described in detail below, the suction forces generated by application of the stored vacuum can be used to aspirate or otherwise remove clot material from within a blood vessel of a human patient.

II. Selected Embodiments of Pressure Sources for Use with Clot Removal Systems

As described in detail above with reference to FIG. 1, the assembly 10 of the present technology includes a pressure source (e.g., a vacuum source, negative pressure source, etc.) configured to charge a vacuum that can be applied to the catheter subsystem 100 to generate suction forces for aspirating clot material from within a blood vessel. In general, the pressure source can be any suitable source or combination of sources for generating and/or storing negative pressure. In some embodiments, the pressure source can be a pump (e.g., an electric pump coupled to a vacuum chamber) while, in other embodiments, the pressure source can include one or more syringes that can be actuated or otherwise activated by a user of the assembly 10 to generate and store a vacuum therein.

FIG. 2 is a side view of a pressure source 240 comprising a vacuum-pressure locking syringe (“syringe 240”) configured in accordance with the present technology. In some embodiments, the syringe 240 can be of the kind sold under the trademark “VacLok” by Merit Medical System, Inc. In the illustrated embodiment, the syringe 240 includes a plunger 242 slidably and rotatably positioned within a chamber or barrel 244. The barrel 244 is shown as transparent in FIG. 2 for the sake of clarity. The plunger 242 includes a seal 243 and a plurality of index members 246 defining slots 248 between adjacent pairs thereof. A tab member 245 projects inwardly from the interior surface of the barrel 244 and is configured to be removably positioned in the slots 248 for locking the plunger 242 in position relative to the barrel 244. In some embodiments, the barrel 244 can be made of a transparent material that permits a user to visualize material (e.g., clot material) within the barrel 244 and to visualize the relative position between the slots 248 and tab member 245 for locking the syringe 240.

Referring to both FIGS. 1 and 2 together, the syringe 240 further includes a tip 247 for coupling the syringe 240 to the tubing subsystem 120. In the illustrated embodiment, the tip 247 is a standard luer connector that can be coupled to the connector 128 via one or more suitable adaptors. The tip 247 further defines a lumen or bore 249 having an inner diameter D₁. In some embodiments, the diameter D₁is about 0.103″, or about 0.080″ to about 0.200″, or about 0.100″ to about 0.150″, or about 0.100″ to about 0.110″. In some embodiments, the inner diameter D₁is about 14 French.

During operation of the assembly 10, a user can first close the fluid control device 126 and then grip the plunger 242 and/or the barrel 244 to withdraw (e.g., retract) the plunger 242 at least partially out of the barrel 244 to thereby generate a vacuum in the barrel 244. Once the user has withdrawn the plunger 242 to a sufficient or desired volume, the user can lock the plunger 242 by rotating the plunger 242 relative to the barrel 244 such that the tab member 245 is positioned within a corresponding one of the slots 248. In other embodiments, the syringe 240 may not be a locking syringe, and the user can instead hold the plunger 242 in position relative to the barrel 244. Moreover, the user can control the volume of the vacuum—by withdrawing the plunger 242 more or less—to provide a desired amount or level of suction/aspiration upon opening of the fluid control device 126. In some embodiments, the syringe has a volume of about 60 cc or less than about 60 cc.

FIG. 3A is a side view of a pressure source 340 comprising a vacuum-pressure locking syringe (“syringe 340”) configured in accordance with the present technology. The syringe 340 can have some features generally similar to the features of the syringe 240 described above with reference to FIG. 2. For example, the syringe 340 includes a plunger 342 slidably and rotatably positioned within a barrel 344, and the plunger 342 includes a plurality of index members 346 defining slots 348 between adjacent pairs thereof. The barrel 344 is shown as transparent in FIG. 3A (and FIG. 3C) for the sake of clarity. While withdrawing the plunger 342, a user can lock the plunger 342 at a specified volume by rotating the plunger 342 relative to the barrel 344 such that a tab member 345 on the interior surface of the barrel 344 is positioned within a corresponding one of the slots 348. In some embodiments, the syringe 340 has a maximum volume of about 60 cc or greater than 60 cc.

In the illustrated embodiment, the syringe 340 includes a large-bore tip 347, such as a Toomey tip, defining an inner lumen or bore 349. In some embodiments, the bore 349 can have an inner diameter D₂that is greater than or equal to the largest inner diameter of the assembly 10 (e.g., of the catheter 102 and tubing subsystem 120). In certain embodiments, the tip 347 can be about 26 French or greater. Accordingly, referring to FIGS. 2 and 3A together, the diameter D₂can be greater than the dimension D₁. For example, the dimension D₂can be about two, three, four, or more times greater than the diameter D₁.

FIG. 3B is a side view of an adaptor 350 for connecting the syringe 340 to the catheter subsystem 100 configured in accordance with the present technology. FIG. 3C is a side view of the adaptor 350 coupled to the syringe 340, and FIG. 3D is a side view of the syringe 340 coupled to the tubing subsystem 120 via the adaptor 350. The adaptor 350 is shown as partially transparent in FIG. 3C for the sake of illustration. Referring to FIG. 3B, the, the adaptor 350 includes (i) a first portion 351 defining a first lumen or bore 352 having an inner diameter D₃, (ii) a second portion 353 defining a second lumen or bore 354, and (iii) a stepped surface or interface 355 between the first and second portions 351, 353. The first portion 351 can further include a seal 357 such as an O-Ring around an exterior surface thereof.

Referring to FIGS. 3A-3D together, the second bore 354 of the adaptor 350 is configured to removably receive the tip 347 of the syringe 340 therein. In some embodiments, the tip 347 can be snuggly received in the second bore 354 via an interference fit. In some embodiments, a seal (e.g., an O-ring) can be positioned between an exterior surface of the tip 347 and an interior surface of the second bore 354. In other embodiments, the syringe 340 can be permanently coupled or integrally formed with the adaptor 350. The first portion 351 of the adaptor 350 is configured to be removably positioned within the connector 128 of the tubing subsystem 120 to fluidly couple the syringe 340 to the tubing subsystem 120. In some embodiments, the first portion 351 of the adaptor 350 can be pushed into the connector 128 until the interface 355 abuts the connector 128. When the first portion 351 of the adaptor 350 is positioned within the connector 128, the seal 357 seals the interface between the connector 128 and the adaptor 350.

The diameter D₃of the first bore 352 of the adaptor 350 can be selected to be about the same as or greater than the greatest inner diameter of the assembly 10 (e.g., of the catheter 102 and the tubing subsystem 120). For example, the catheter 102 can be about 9 French or greater, and the diameter D₃can be selected to be larger than the size of the catheter 102. Accordingly, when the fluid control device 126 is open, the continuous lumen between the catheter 102 and the syringe 340 can have a generally constant diameter and/or does not contain any narrowing at the interface between the syringe 340 and the tubing subsystem 120. That is, the adaptor 350 can connect the syringe 340 and the tubing subsystem 120 without any restriction or narrowing of the fluid path. In contrast, a standard luer connector (e.g., the syringe 240) can only provide a continuous lumen for catheters of about 8 French or smaller. Any narrowing of the fluid pathway between the catheter 102 and the syringe 340 can reduce the volumetric flow rate (e.g., suction forces and fluid velocities) that can be generated when a vacuum stored in the syringe 340 is applied to the catheter 102.

In general, the syringe 340 and the adaptor 350 can reduce the fluid resistance in the assembly 10 and therefore facilitate a more rapid pressure equalization in the assembly 10 when the fluid control device 126 is opened to apply the charged vacuum to the catheter 102. In some embodiments, for example, when the syringe 240 (FIG. 2) is charged with a 60 cc vacuum and the fluid control device 126 is opened, the pressure in the assembly 10 can take about 1-2 seconds to equalize. In contrast, when the syringe 340 is charged with a 60 cc vacuum and the fluid control device 126 is opened, the pressure in the assembly 10 can take less than about 1 second (e.g., about 0.5 seconds) to equalize. More specifically, Table 1 illustrates representative pressure equalization times and associated flow rates when the syringe 240 is coupled to a 20 French catheter (i.e., the catheter 102). Table 2 illustrates representative pressure equalization times and associated flow rates when the syringe 340 and the adaptor 350 are coupled to a 20 French catheter (i.e., the catheter 102).

TABLE 1

Pressure Equalization Time (seconds)
Flow Rate (cc/sec)

2.0
30.0

1.9
31.6

1.8
33.3

1.7
35.3

1.6
37.5

1.5
40.0

1.4
42.9

1.3
46.2

TABLE 2

Pressure Equalization Time (seconds)
Flow Rate (cc/sec)

0.9
66.7

0.8
75.0

0.7
85.7

0.6
100.0

0.5
120.0

0.4
150.0

0.3
200.0

0.2
300.0

0.1
600.0

In each instance, the syringe 340 provides for relatively faster equalization times and correspondingly greater flow rates. It is expected that the more rapid pressure equalization and flow rates provided by the syringe 340 will provide correspondingly greater suction forces at the distal portion 103a of the catheter 102. That is, in general, it is expected that increasing the bore size of a syringe used to provide vacuum pressure will provide greater suction forces over a smaller period of time (e.g., will provide a larger vacuum impulse). In some embodiments, the greater suction forces can facilitate the removal of clot material from a blood vessel of a patient even where the clot material is strongly lodged or attached within the blood vessel (e.g., a chronic clot).

Moreover, as shown in FIG. 3D, the adaptor 350 can couple the syringe 340 to the connector 128 without the need for any intervening tubing sections or additional adaptors. This arrangement can minimize the total length, volume, etc., of the components fluidly coupling the catheter 102 to the syringe 340. It is expected that the magnitude of suction forces generated at the distal portion 103a of the catheter 102—e.g., when a vacuum charged in the syringe 340 is applied to the catheter 102 by opening of the fluid control device 126—is proportional to the length of the fluid path between the pressure source 340 and catheter 102. Thus, operation of the assembly 10 with the syringe 340 and adaptor 350 is expected to increase the suction forces generated at the distal portion 103a of the catheter 102. In some embodiments, the greater suction forces can facilitate the removal of clot material from a blood vessel of a patient even where the clot material is strongly lodged or attached within the blood vessel (e.g., a chronic clot).

FIG. 4A is a side perspective view a pressure source 400 including the syringe 340 (“primary syringe 340”) shown in FIGS. 3A-3D and a secondary syringe 460 configured in accordance with the present technology. The secondary syringe 460 can include a plunger 462 slidably positioned within a chamber or barrel 464. The primary and secondary syringes 340, 460 can have the same volume or different volumes. In the illustrated embodiment, a tip 463 of the secondary syringe 460 is coupled to a first one-way valve (e.g., a check valve) 470 via a coupling member 465, such as a tube. The first one-way valve 470 is configured to fluidly connect the secondary syringe 460 to the ambient environment or another device coupled to the first one-way valve 470. A second one-way valve (e.g., a check valve) 472 spans between and is configured to fluidly connect the primary syringe 340 to the secondary syringe 460. More specially, in the illustrated embodiment the second one-way valve 472 is connected between the first portion 351 of the adaptor 350 and the coupling member 465. In other embodiments, the second one-way valve 472 can couple the primary and secondary syringes 340, 460 in different manners. For example, the second one-way valve 472 can span between and directly connect the barrels 344,464. The primary and secondary syringes 340, 460 can be coupled or fastened together via one or more connectors 474 that fix the positions of the barrel 344, 464 relative to one another.

In some embodiments, the second one-way valve 472 is a normally-open check valve configured to (i) permit fluid (e.g., air) flow from the primary syringe 340 and the adaptor 350 to the secondary syringe 460 and (ii) inhibit fluid flow in the opposite direction from the secondary syringe 460 into the primary syringe 340. In some embodiments, the second one-way valve 472 has a cracking (e.g., opening) pressure of about 0 psi. In one aspect of the present technology, this arrangement maximizes the magnitude of the vacuum that can be charged within the primary syringe 340. That is, the cracking pressure of the second one-way valve 472 does not reduce the effective vacuum within the primary syringe 340. In other embodiments a normally-closed or other type of valve could be used for the second one-way valve 472. However, in such embodiments the vacuum efficiency of the pressure source 400 would be reduced by the cracking pressure of the second one-way valve 472. Similarly, the first one-way valve 470 can be a check valve configured to (i) permit fluid flow from the secondary syringe 460 to the ambient environment (or other device) and (ii) inhibit fluid flow in the opposite direction from the ambient environment into the secondary syringe 460.

FIGS. 4B and 4C are enlarged schematic side views of the pressure source 400 during operation. More specifically, FIGS. 4B and 4C illustrate fluid flow paths through the first and second one-way valves 470, 472 during retraction and advancement, respectively, of the plunger 462 through the barrel 464 of the secondary syringe 460. Referring first to FIGS. 4A and 4B together, during retraction/withdrawal of the plunger 462, (i) the first one-way valve 470 is closed to inhibit fluid from flowing into the secondary syringe 460 while (ii) the second one-way valve is open 472 to permit fluid to flow from the primary syringe 340, the catheter subsystem 100 (FIG. 1), and/or the tubing subsystem 120 (FIG. 1) into the secondary syringe 460. This flow path is indicated by the arrows R in FIG. 4B. Referring to FIGS. 4A and 4C together, during advancement of the plunger 462, (i) the first one-way valve 470 is open to permit fluid flow (e.g., fluid expulsion) from the secondary syringe 460 to the ambient environment (or other device) while (ii) the second one-way valve 472 is closed to inhibit fluid flow from the secondary syringe 460 into (e.g., back into) the primary syringe 360, the catheter subsystem 100, and/or the tubing subsystem 120. This flow path is indicated by the arrows A in FIG. 4C.

Referring to FIGS. 1 and 3A-4C together, the pressure source 400 can be coupled to the tubing subsystem 120 by coupling the primary syringe 340 to the connector 128 (e.g., as shown in FIG. 3D). When the pressure source is coupled to the tubing subsystem 120, retraction of the plunger 462 of the secondary syringe 460 evacuates an evacuatable volume of the assembly 10. For example, when the fluid control device 126 is closed, retraction of the plunger 462 of the secondary syringe 460 evacuates fluid, through the second one-way valve 472, from (i) the primary syringe 340 (e.g., from the barrel 344, the tip 347, and/or the adaptor 350) and (ii) the portion of the tubing subsystem 120 between the fluid control device 126 and the primary syringe 340. This can enable a greater charged/stored vacuum to be generated for subsequent application to the catheter subsystem 100 for aspirating clot material. In some embodiments, the plunger 462 of the secondary syringe 460 can be withdrawn/advanced (e.g., “cycled”) one or more times before withdrawing the plunger 342 of the primary syringe 340 to evacuate air from (i) the tip 347 of the primary syringe 340 and/or (ii) the portion of the tubing subsystem 120 between the fluid control device 126 and the tip 347. In other embodiments, the plunger 462 of the secondary syringe 460 can alternatively or additionally be withdrawn after withdrawing the plunger 342 of the primary syringe 340 to further evacuate the barrel 344 of the primary syringe 340. In some embodiments, the plunger 462 can be cycled when the fluid control device 126 is open to, for example, facilitate the removal of clot material stuck or clogged within the catheter subsystem 100. That is, cycling the secondary syringe 460 when the fluid control device 126 is open can generate vacuum pressure and suction in the catheter 102 to aid in the aspiration/removal of clot material.

In some embodiments, the volumes of the primary and secondary syringes 340, 460 can be selected based on one or more desired characteristics of a clot removal procedure using the pressure source 400. For example, the secondary syringe 460 can have a larger volume than the primary syringe 340 to permit a high vacuum to be charged within the primary syringe 340 while also limiting blood loss from the patient.

In one aspect of the present technology, the pressure source 340 permits a greater vacuum to be generated without increasing the volume of the primary syringe 340. For example, the vacuum generated by the primary syringe 340 alone is directly proportional to the volume of the primary syringe 340. Thus, to generate a greater vacuum using the primary syringe 340 alone, the volume of the primary syringe 340 must be increased. In contrast, inclusion of the secondary syringe 460 in the pressure source 400 and the configuration of the first and second one-way valves 470, 472 allows the (e.g., maximum) generated vacuum to be independent of the volume of the primary syringe 340. Therefore, for example, the generated vacuum can be increased without correspondingly increasing the volume of blood withdrawn from the patient when applying the vacuum to the catheter subsystem 100.

In some embodiments, (e.g., as described in greater detail below with reference to FIG. 19), the primary syringe 340 of the pressure source 400 can be replaced with a simple pressure vessel or other volume, such as a canister, barrel, tube, etc. In such embodiments, a vacuum can be generated in the canister simply by cycling the secondary syringe 460 one or more times. In some embodiments, the secondary syringe 460 can comprise a pump or vacuum source other than a syringe. Likewise, the secondary syringe 460 or other vacuum source can be fluidly coupled to the primary syringe 340 in other manners (e.g., via a different arrangement of check valves) to produce the same or similar flow patterns as shown in FIGS. 4B and 4C. Moreover, in some embodiments the first and second one-way valves 470, 472 can be other types of flow control devices that are mechanically activated/deactivated (e.g., opened and closed) rather than passively operated via pressure differentials within the pressure source 400. For example, the flow control devices 470, 472 can be mechanically coupled to the plunger 462 of the secondary syringe 460 such that cycling the plunger 462 activates/deactivates the flow control devices 470, 472 to operate the pressure source 400 in the manner illustrated in FIGS. 4B and 4C.

FIG. 5 is a side cross-sectional view of a pressure source 540 comprising an automatic release syringe (“syringe 540”) configured in accordance with the present technology. In general, the syringe 540 is configured to automatically apply a charged vacuum of a selected volume to the catheter subsystem 100 without requiring the actuation of an intervening fluid control device, such as the fluid control device 126 shown in FIG. 1. The syringe 540 can have some features generally similar to the features of the syringes 240, 340 described in detail above with reference to FIGS. 2 and 3A-3D. For example, the syringe 540 includes a first plunger 542 slidably positioned within a chamber or barrel 544. The first plunger 542 further includes a first seal 543 that engages an interior surface of the barrel 544 such that a vacuum is formed within the barrel 544 as the first plunger 542 is withdrawn through the barrel 544. Likewise, referring to both FIGS. 1 and 5 together, the syringe 540 includes a tip 547 (e.g., a Toomey tip) for coupling the syringe 540 to the tubing subsystem 120 (e.g., via a Toomey tip adaptor) and defining a bore 549. In some embodiments, the bore 549 has a relatively large diameter selected to provide rapid pressure equalization in the assembly 10 after a vacuum stored in the syringe 540 is released.

The first plunger 542 can further include (i) a grip portion 541 configured to be engaged by a user for retracting the first plunger 542 and (ii) a lumen 581 extending lengthwise therethrough. In the illustrated embodiment, a plunger assembly 582 is slidably positioned within and extends through the lumen 581 of the first plunger 542. The plunger assembly 582 includes (i) a second plunger 583 and (ii) a release member 584 slidably and/or rotatably positioned within a lumen 585 of the second plunger 583. The release member 584 includes an engagement member 586 configured to engage the grip portion 541 of the first plunger 542 when the first plunger 542 is withdrawn from the barrel 544. The second plunger 583 includes a second seal 587 configured to engage and seal an interior surface of the bore 549 of the syringe 540 to enable a vacuum to be formed in the barrel 544 as the first plunger 542 is withdrawn through the barrel 544. That is, the second seal 587 can seal (e.g., fluidly disconnect) the barrel 544 of the syringe from the tubing subsystem 120 and the catheter subsystem 100. In some embodiments, the syringe 540 can further include an O-ring 579 or other suitable component for sealing an interface between the first and second plungers 542, 582 to maintain the vacuum formed within the barrel 544, while also permitting the first plunger 542 to move (e.g., translate) relative to the second plunger 583.

The plunger assembly 582 further includes a locking mechanism (not shown) configured to permit/inhibit the release member 584 from moving longitudinally relative to the second plunger 583. In some embodiments, for example, rotation of the release member 584 in a first direction relative to the second plunger 583 can lock the two components in position, while rotation of the release member 584 in a second direction relative to the second plunger 583 can unlock the two components so that the release member 584 can be withdrawn or pushed into the lumen 585 of the second plunger 583. In other embodiments, the release member 584 and the second plunger 583 can be integrally formed or permanently locked together.

The plunger assembly 582 enables (i) a user of the syringe 540 to select a desired volume for a vacuum to be formed in the syringe 540 and (ii) the automatic release or application of a generated vacuum via opening (e.g., unplugging) of the bore 549. Specifically, during operation of the syringe 540, a user can first unlock the release member 584 and slide the release member 584 to a position corresponding to a desired vacuum volume. For example, the release member 584 can have tick marks 588 or other indicia along its length that correspond to a volume of the syringe 540 (e.g., a vacuum chamber volume). After selecting a desired volume, the user can lock the release member 584 relative to the second plunger 583 (e.g., by rotating the release member 584) to inhibit relative movement of the two components. After locking the release member 584, the user can grasp the grip portion 541 to retract the first plunger 542 relative to the barrel 544 and the plunger assembly 582 to generate a vacuum within the barrel 544 between the first and second seals 543, 587. When the first plunger 542 has been retracted to the desired volume, the grip portion 541 engages the engagement member 586 of the release member 584 such that further retraction of the first plunger 542 simultaneously retracts the plunger assembly 582. As the plunger assembly 582 is retracted, the second seal 587 of the second plunger 583 is pulled out of the bore 549, thereby releasing the vacuum stored in the barrel 544. In this manner, the syringe 540 provides for the automatic release of charged vacuum pressure at a specified volume and with a single retraction of the first plunger 542. Put differently, the syringe 540 has a built-in fluid control device and thus eliminates the need for a separate fluid control device 126 and/or an additional step for opening the fluid control device 126.

FIG. 6 is a top perspective view of a pressure source 640 comprising a syringe (“syringe 640”) configured in accordance with the present technology. The syringe 640 can include some features generally similar to the features of the syringes 240, 340, and 540 described in detail above with reference to FIGS. 2-3D and 5. For example, the syringe 640 includes a plunger 642 slidably positioned within a barrel 644, and a tip 647 (e.g., a large-bore tip). In the illustrated embodiment, the syringe 640 further includes a lever or handle 690 operably coupled to the plunger 642. The handle 690 provides mechanical leverage for withdrawing the plunger 642 to create a vacuum within the barrel 644. More specifically, the handle 690 can be coupled to a crossbar 691 that rotates relative to the plunger 642 via actuation (e.g., rotation) of the handle 690. The crossbar 691 can be coupled to a gear (obscured in FIG. 6) configured to engage a track 692 on the plunger 642. Accordingly, rotation of the handle 690 in a first direction retracts the plunger 642 relative to the barrel 644 to charge a vacuum in the barrel 644. And, rotation of the handle 690 in a second (e.g., opposite) direction advances the plunger 642 into the barrel 644 to, for example, expel fluid, material, etc., from the barrel 644.

In one aspect of the present technology, the handle 690 provides additional mechanical leverage relative to a standard syringe, and can thus reduce the force (e.g., strain, energy, etc.) required by a user of the syringe 640 to form a vacuum in the syringe 640. Therefore, use of the syringe 640 can reduce the time needed to remove clot material with the assembly 10. In some embodiments, the syringe 640 can have a volume greater than 60 cc (e.g., greater than 80 cc, greater than 100 cc, greater than 120 cc, greater than 140 cc, etc.). In a particular embodiment, for example, the syringe 640 can have a volume of about 140 cc. With such large volumes, it may be difficult for some users to manually retract the plunger 642 without the additional mechanical leverage provided by the handle 690. Thus, the syringe 640 can enable the use of larger volume syringes that can generate correspondingly greater suction forces in the catheter subsystem 100.

Referring again to FIG. 1, it is expected that less tortuous (e.g., more linear) fluid paths between the pressure source 140 and the catheter subsystem 100 will produce greater suction forces and corresponding fluid velocities at the distal portion 103a of the catheter 102 when stored vacuum pressure is applied to the catheter subsystem 100. Accordingly, in some embodiments the side port 108 of the valve 106 can be formed to have an angle A that is less than about 90°, less than about 75°, less than about 60°, less than about 45°, less than about 30°, less than about 15° etc. Reducing the relative angle between the side port 108 and the lumen 109 of the valve 106 (and thus the lumen 104 of the catheter 102) reduces the tortuosity of the fluid path between the pressure source 140 and the catheter 102. Moreover, in some embodiments, the pressure source 140 can be coupled to the proximal portion 107b of the valve 106 instead of or in addition to the side port 108 to provide a more linear fluid path between the pressure source 140 and the catheter 102. For example, FIG. 24 is an enlarged isometric view of the assembly 10 showing the pressure source 340 coupled directly to the proximal portion 107b of the valve rather than to the connector 128 of the tubing subsystem 120 and the side port 108 of the valve 106. Although the pressure source 340 is illustrated in FIG. 24, any of the pressure sources described in detail above with reference to FIGS. 2-6 can be configured to be coupled to the proximal portion 107b of the valve 106 rather than the side port 108. In other embodiments, the side port 108 can be omitted and the valve 106 and the tubing subsystem 120 can be coupled to the catheter 102 via a Y-connector. For example, FIG. 25 is an enlarged isometric view of the assembly 10 showing the valve 106 and the tubing subsystem 120 coupled to the catheter 102 via a Y-connector 2590. In yet other embodiments, the tubing system 120 is linearly coupled to the catheter 102, and the valve 106 protrudes at an angle from the catheter 102.

In some embodiments, however, a guidewire or other component is positioned within the valve 106 during the duration of a clot removal procedure (e.g., for delivering interventional devices to a treatment site within a patient). Accordingly, in some embodiments, to facilitate coupling of the pressure source 140 to the proximal portion 107b of the valve 106—even when a guidewire is inserted therethrough—the pressure source 140 can be a syringe configured for over-wire delivery. For example, FIG. 7 is a side view of a pressure source 740 comprising a vacuum-pressure locking syringe (“syringe 740”) configured in accordance with the present technology for delivery and operation over a guidewire 794. The syringe 740 can have some features generally similar to the features of the syringe 340 described in detail above with reference to FIG. 3. For example, the syringe 740 includes a plunger 742 slidably and rotatably positioned within a barrel 744. The barrel 744 is shown as transparent in FIG. 7 for the sake of clarity. In the illustrated embodiment, the plunger 742 includes a lumen 796 (shown in broken lines) extending longitudinally therethrough. The guidewire 794 can be inserted through the lumen 796 of the plunger 742 such that the syringe 740 can be advanced over the guidewire 794 for attachment to the proximal portion 107b of the valve 106. The syringe 740 can further include one or more sealing components (e.g., valves, O-rings, etc.; not shown) for maintaining a seal between the guidewire 794 and the plunger 742 to permit build-up and storage of a vacuum in the barrel 744.

In general, one skilled in the art will understand that the various embodiments of pressure sources disclosed herein may be combined to, for example, include multiple pressure sources or pressure sources having different components or combinations of components. For example, in some embodiments the secondary syringe 460 (FIGS. 4A-4C) can be coupled via one or more one-way valves to the syringes 240, 540, 640 or 740 (FIGS. 2 and 5-7, respectively) to generate additional vacuum. In some embodiments, multiple pressure sources can be coupled to the catheter 102 via the tubing subsystem 120 and/or via the valve 106. Moreover, the individual pressure sources can be the same or different, and can be coupled to the catheter subsystem 100 via a single fluid control device, such as the fluid control device 126, or can be coupled to the catheter subsystem 100 via separate fluid control devices. Therefore, the profile of the vacuum applied to the catheter 102 can be selected or adjusted by using multiple different pressure sources. For example, a specific vacuum profile can depend at least on (i) the individual characteristics of the multiple pressure sources (e.g., volume, bore-size, etc.), (ii) the manner in which the pressure sources are coupled to the catheter subsystem 100 (e.g., via individual valves, via the same valve, etc.), and (iii) the timing of the application or release of the vacuum of each pressure source to the catheter subsystem 100 (e.g., staggered release, simultaneous release, etc.). As one example, in some embodiments, the syringe 240 (FIG. 2) and the syringe 340 (FIG. 3) can both be coupled to the tubing subsystem 120 via, for example, a Y-connector. After charging both syringes 240, 340 with vacuum pressure, opening the fluid control device 126 can simultaneously apply the combined vacuum to the catheter 102. The larger-bored syringe 340 can provide a short but powerful impulse of vacuum pressure, while the smaller-bored syringe 240 can provide a longer and more sustained vacuum pull. This combination can apply a large, fast-acting suction force to dislodge and capture clot material in the catheter 102, and simultaneously apply a more sustained suction force to capture more clot material.

III. Selected Embodiments of Methods of Clot Removal

FIG. 8 is a flow diagram of a process or method 800 for operating a clot removal system including the assembly 10 to remove clot material from within a blood vessel (e.g., a pulmonary blood vessel) of a human patient in accordance with the present technology. FIGS. 9A-9C are side views of a proximal portion of the assembly 10, and FIGS. 10A and 10B are schematic illustrations of a distal portion of the assembly 10, during a clot removal procedure in accordance with embodiments of the present technology. In particular, FIGS. 9A-9C are side views of the assembly 10 including the syringe 340 and adaptor 350 (FIGS. 3A-3D), and FIGS. 10A and 10B are side views of the catheter 102 with the distal portion 103a of the catheter 102 positioned proximate to an embolism or clot material PE within a blood vessel BV (e.g., a pulmonary blood vessel). Although some features of the method 800 are described in the context of the embodiments shown in FIGS. 1, 3A-3D, and 9A-10B for the sake of illustration, one skilled in the art will readily understand that the method 800 can be carried out using other suitable systems and/or devices described herein. In particular, although described in the context of the syringe 340, the method 800 can be carried out using any one or combination of the pressure sources described in detail above with reference to FIGS. 2-7.

At block 802, the method 800 includes positioning the distal portion 103a of the catheter 102 proximate to clot material within a blood vessel of a human patient (e.g., at a treatment site). For example, in the embodiment illustrated in FIG. 10A, a distal terminus of the distal portion 103a of the catheter 102 is positioned proximate to a proximal portion of the clot material PE. It is expected that reducing the distance between the distal terminus of the catheter 102 and the proximal portion of the clot material PE—without contacting the clot material PE with the catheter 102—will maximize the suction forces on the clot material PE when the fluid control device 126 is opened. It is also expected that reducing the distance (e.g., clearance) between the inner diameter of the blood vessel BV and the outer diameter of the catheter will maximize the suction forces on the clot material PE. However, in other embodiments, the distal terminus of the catheter 102 can be positioned at least partially within the clot material PE, or the distal terminus of the catheter 102 can be positioned distal of the clot material PE.

Access to the pulmonary vessels can be achieved through the patient's vasculature, for example, via the femoral vein. In some embodiments, the catheter subsystem 100 can include an introducer (e.g., a Y-connector with a hemostasis valve; not shown) that can be partially inserted into the femoral vein. A guidewire (not shown) can be guided into the femoral vein through the introducer and navigated through the right atrium, the tricuspid valve, the right ventricle, the pulmonary valve, and into the main pulmonary artery. Depending on the location of the embolism, the guidewire can be guided to one or more of the branches of the right pulmonary artery and/or the left pulmonary artery. In some embodiments, the guidewire can be extended entirely or partially through the clot material PE. In other embodiments, the guidewire can be extended to a location just proximal of the clot material PE. After positioning the guidewire, the catheter 102 can be placed over the guidewire and advanced (e.g., as indicated by arrow A1) to a position proximate to the clot material PE as illustrated in FIG. 10A.

In some embodiments, to confirm the position of the distal portion 103a of the catheter 102, a contrast agent can be injected through the catheter 102 and viewed using fluoroscopic imaging techniques, as is known in the art. In some embodiments, the valve 106 can be opened to determine the position of the distal portion 103a of the catheter 102 relative to the clot material PE. For example, the activation buttons 101 can be depressed to open the lumen 109 of the valve 106. If there is substantially no back-bleeding through the valve 106, the operator can determine that the distal portion 103a of the catheter 102 is fully engaged with the clot material PE. Conversely, if there is some back-bleeding through the valve 106, the operator can determine that the distal portion 103a of the catheter is not fully engaged with the clot material PE. Accordingly, to locate the distal portion 103a of the catheter 102 just proximal of the clot material PE, the operator can (i) first determine that distal portion 103a of the catheter is fully engaged with the clot material PE by activating the valve 106 and detecting no back-bleeding and (ii) then reposition the catheter 102 (e.g., by withdrawing the catheter 102 proximally) and activate the valve 106 until back-bleeding is detected—thereby confirming that the distal portion 103a of the catheter 102 is positioned proximal of the clot material PE. In some embodiments, the valve 106 can be opened during retraction of the catheter 102 until back-bleeding is detected. In other embodiments, the valve 106 can be closed during retraction of the catheter 102, and the catheter 106 can be retracted a set (e.g., predetermined) distance before the valve 106 is opened again. In one aspect of the present technology, determining the position of the distal portion 103a of the catheter 102 via activation of the valve 106 can be used when it is difficult to determine the position of the catheter 102 via radiographic techniques. In contrast, many conventional hemostasis valves cannot be activated in this manner.

In some embodiments, the guidewire can then be withdrawn while, in other embodiments, the guidewire can remain and can be used to guide other catheters (e.g., delivery catheters, additional aspiration catheters, etc.), interventional devices, etc., to the treatment site. It will be understood, however, that other access locations into the venous circulatory system of a patient are possible and consistent with the present technology. For example, the user can gain access through the jugular vein, the subclavian vein, the brachial vein, or any other vein that connects or eventually leads to the superior vena cava. Use of other vessels that are closer to the right atrium of the patient's heart can also be advantageous as it reduces the length of the instruments needed to reach the pulmonary embolism.

At block 804, the method 800 includes coupling a pressure source (e.g., the syringe 340) to the catheter 102 via the fluid control device 126. For example, in the embodiment illustrated in FIG. 9A, the tip 347 (shown in FIGS. 3A and 3C but obscured in FIG. 9A) of the syringe 340 can be coupled to the connector 128 via the adaptor 350. Once the syringe 340 is coupled to the catheter 102, (i) opening the fluid control device 126 fluidly connects the syringe 340 to the lumen 104 of the catheter 102, and (ii) closing the fluid control device 126 fluidly disconnects the syringe 340 from the lumen 104 of the catheter 102. The fluid control device 126 is in an open position in FIG. 9A.

At block 806, the method 800 includes activating the syringe 340 to generate a vacuum while the fluid control device 126 is closed. For example, as shown in FIG. 9B, the user can first actuate the fluid control device 126 to close the fluid control device 126, and then retract the plunger 342 to generate a vacuum in the barrel 344 of the syringe 340. The user can subsequently lock the plunger 342 relative to the barrel 344, as described in detail above, to store or maintain a vacuum of known volume in the syringe 340. In this manner, the syringe 340 can be pre-charged with a vacuum before the vacuum is applied to the catheter 102. In contrast, many conventional aspiration techniques include activating a negative pressure source (e.g., a pump, a syringe, etc.) while the pressure source is fluidly connected to a lumen to be aspirated. In some embodiments, when the pressure source 400 with the secondary syringe 460 (FIGS. 4A-4C) is used with the primary syringe 340; the secondary syringe 460 can be cycled one or more times before or after retracting the plunger 342 to increase the vacuum pressure.

At block 808, the method 800 includes opening the fluid control device 126 to apply the vacuum to the lumen 104 of the catheter 102. For example, with reference to FIG. 9C, the user can actuate (e.g., twist a handle of) the fluid control device 126 to open the fluid control device 126 and apply the vacuum stored in the syringe 340 to the catheter subsystem 100. As shown in FIG. 10B, application of the vacuum causes suction at the distal tip 103a of the catheter 102 (e.g., as indicated by arrow A2) that aspirates at least a portion of the clot material PE from the blood vessel BV and into the lumen 104 of the catheter 102. In some embodiments, opening the fluid control device 126 instantaneously or nearly instantaneously generates suction at the distal portion 103a of the catheter 102. In certain embodiments, application of the vacuum can generate suction for less than about 1 second (e.g., about 0.5 second), substantially less than about 1 second (e.g., about 0.3 second, about 0.1 second, etc.) less than about 2 seconds, or greater than about 2 seconds—until the pressure in the assembly 10 equalizes. In some embodiments, depending on the volume of the vacuum chamber formed in the syringe 340 and the dimensions of the catheter subsystem 100 and the tubing subsystem 120 (e.g., where the syringe 340 has a volume that is greater than or about equal to a volume of the catheter subsystem 100), at least some of the clot material PE can be aspirated entirely through the lumen 104 of the catheter 102 and into the barrel 344 of the syringe 340. In some such embodiments, the user can determine whether subsequent steps for treating the clot material PE are necessary or desirable by visualizing the amount of clot material collected in the syringe 340. FIG. 9C, for example, illustrates the syringe 340 and the tubing subsystem 120 after the fluid control device 126 has been opened to apply the vacuum stored in the syringe 340 to the catheter 102. In the illustrated embodiment, some of the clot material PE is visible in the syringe 340.

In some embodiments, the fluid control device 126 or another fluid control device can be intermittently operated to provide discrete bursts of suction. For example, the fluid control device 126 can be quickly opened and closed to provide a first burst of suction (e.g., vacuum release) without fully equalizing the pressure in the assembly 10. The fluid control device 126 can then be opened again to provide a second burst of suction, or opened and closed repeatedly to provide a desired suction pattern. In some embodiments, the assembly 10 can be specifically configured to facilitate the application of multiple bursts of suction. For example, (i) the fluid control device 126 can be spring-loaded, electronically controlled, etc., to rapidly open and close the valve, and/or (ii) the pressure source 140 can have a large vacuum chamber and/or small bore size to increase the time required for pressure in the assembly 10 to equalize (e.g., to increase a discharge time of the pressure source 140).

Sometimes, as shown in FIG. 10B, discharging the vacuum stored in the pressure source to aspirate the lumen 104 of the catheter 102 may not remove all of the clot material PE (or a desired amount of the clot material PE) from the blood vessel BV. That is, a single aspiration may not adequately remove the clot material PE from the blood vessel BV. In such instances, the user of the assembly 10 may wish to again apply vacuum pressure (conduct an “aspiration pass”) to remove all or a portion of the remaining clot material PE in the blood vessel BV. In such instances, the pressure source can be disconnected from the tubing subsystem 120 and drained (e.g., aspirated clot removal removed) before the method 800 returns to block 802. For example, the adaptor 350 and the syringe 340 can be decoupled from the connector 128, and the plunger 342 can be pushed into the barrel 344 to expel the clot material PE and associated fluid from the barrel 344 via the tip 347. With the distal portion of the catheter 102 positioned proximate to the remaining clot material PE (e.g., unmoved relative the last aspiration pass), the pressure source can then be re-coupled to the connector 128 (block 804), primed again (block 806), and the vacuum pressure discharged (block 808) to aspirate all or a portion of the remaining clot material PE.

Blocks 802-808 can be repeated until a desired amount of clot material is removed from the patient or until the catheter 102 becomes clogged. In some embodiments, to check for clogging of the catheter 102, the fluid control device 126 and/or the valve 106 can be opened to check for back bleeding. A lack of back bleeding can indicate that the catheter 102 is likely clogged. Similarly, if the barrel 344 of the syringe 340 contains mostly air and relatively little blood and clot material (e.g., less than 5-10 cc) after aspiration of the catheter 102 (block 808), it can indicate that the catheter 102 is likely clogged. When the catheter 102 is clogged or a sufficient amount of clot material PE has been removed from the patient, the method 800 can proceed to block 810 and the catheter 102 can be removed from the patient. When the catheter 102 is clogged, the catheter 102 can be flushed and cleared prior to reentry into the patient (block 802). In other embodiments, a different (e.g., new, unused, etc.) catheter can be inserted into the patient and positioned to remove the remaining clot material PE from the patient.

In some embodiments, rather than removing the catheter 102 from the patient if the catheter 102 is clogged, the syringe 340 can be recharged and used to apply one or more subsequent vacuum pulses to the catheter 102. More specifically, the fluid control device 126 can be closed and the syringe 340 can be removed from the connector 128 and evacuated to remove the clot material and blood therein. Then, blocks 804-808 can be repeated to apply another pulse of vacuum to the catheter 102. That is, rather than removing the catheter 102 after a clog is detected, the syringe 340 can be “cycled” until the vacuum force on the clot material PE overcomes the forces between the clot material PE and the catheter 102 and sucks the clot material PE into the syringe 340. In some embodiments, when the pressure source 400 with the secondary syringe 460 (FIGS. 4A-4C) is used with the primary syringe 340, the secondary syringe 460 can be cycled one or more times to increase the vacuum in the assembly 10 (e.g., in the catheter 102) and thus increase the suction force exerted against the clot material PE. That is, rather than removing the catheter 102 after a clog is detected, the secondary syringe 460 can be cycled until the vacuum force on the clot material PE overcomes the forces between the clot material PE and the catheter 102 and sucks the clot material PE into the syringe 340. In some embodiments, as described in detail below with reference to FIGS. 15-16E, a second clot removal assembly can be telescoped through the first assembly 10 to facilitate removal of the clogged clot material PE.

In some embodiments, an interventional device such as a clot removal and/or clot treatment device can be delivered to the treatment site through the catheter 102 for engaging and facilitating clot removal before and/or after application of a stored vacuum to the catheter 102. Suitable interventional devices and associated methods are disclosed in U.S. Pat. No. 9,526,864, filed Jun. 9, 2015, and titled “RETRACTION AND ASPIRATION DEVICE FOR TREATING EMBOLISM AND ASSOCIATED SYSTEMS AND METHODS,” and U.S. Pat. No. 8,784,434, filed Mar. 15, 2013, and titled “METHODS AND APPARATUS FOR TREATING EMBOLISM,” both of which are incorporated herein by reference in their entireties. In some embodiments, for example, the user can first advance an interventional device to the treatment site and at least partially engage the clot material PE with the interventional device to loosen (e.g., scour) the clot material PE. Such loosening of the clot material PE can facilitate the removal of the clot material PE upon a subsequent aspiration pass. Likewise, in some embodiments, the user can use an interventional device to engage residual clot material PE (FIG. 10B) after a first aspiration pass.

IV. Selected Embodiments of Telescoping Clot Removal Systems and Associated Methods of Clot Removal

FIG. 11 is a partially schematic side view of another clot treatment or clot removal system configured in accordance with the present technology. In the illustrated embodiment, the clot removal system includes a first aspiration assembly 20 and a second aspiration assembly 30. The first and second aspiration assemblies 20, 30 (“assemblies 20, 30”) can include some features generally similar to the features of the aspiration assembly 10 described in detail above with reference to FIGS. 1-10B. For example, the first aspiration assembly 20 includes (i) a first catheter subsystem 1000 having a first catheter 1002 and a first valve 1006, (ii) a first tubing subsystem 1020 having a first fluid control device 1026 (e.g., a stopcock), and (iii) a first pressure source 1040 that can be fluidly coupled to the first catheter subsystem 1000 via the first tubing subsystem 1020. Likewise, the second aspiration assembly 30 includes (i) a second catheter subsystem 1100 having a second catheter 1102 and a second valve 1106, (ii) a second tubing subsystem 1120 having a second fluid control device 1126 (e.g., a stopcock), and (iii) a second pressure source 1140 that can be fluidly coupled to the second catheter subsystem 1100 via the second tubing subsystem 1120.

The first and second catheters 1002, 1102 each comprise an elongated shaft defining a lumen 1004, 1104 and having a distal portion 1003a, 1103a, respectively. The first and second valves 1006, 1106 each include (i) a distal portion 1007a, 1107a, (ii) a proximal portion 1007b, 1107b, (iii) a lumen 1009, 1109 extending therethrough, and (iv) a flow controller (obscured in FIG. 10) in the lumen 1009, 1109, respectively. The first fluid control device 1026 is operable to regulate or control fluid flow between (e.g., fluidly connect or disconnect) the first pressure source 1040 and the first catheter subsystem 1000. The second fluid control device 1126 is operable to regulate or control fluid flow between (e.g., fluidly connect or disconnect) the second pressure source 1140 and the second catheter subsystem 1100.

In the illustrated embodiment, the second catheter 1102 has a smaller cross-sectional dimension (e.g., diameter) than the first catheter 1002 so that the second catheter 1102 can be inserted through the first valve 1006 and into the lumen 1004 of the first catheter 1002. In some embodiments, the second catheter 1102 can be telescoped through the lumen 1004 of the first catheter 1002 until the distal portion 1103a of the second catheter 1102 extends beyond a distal terminus of the first catheter 1002. Accordingly, the second catheter 1102 can be longer than the first catheter 1002. In some embodiments, the second catheter 1102 can have a size of 16 French or smaller and the first catheter 1002 can have a size of 20 French or greater. The first valve 1006 can provide a hemostatic seal that inhibits fluid flow (e.g., blood flow) through the first valve 1006 and from the first catheter subsystem 1000 when the second catheter 1102 is positioned within the first catheter 1002. In some embodiments (e.g., as described in detail below with reference to FIGS. 14A-14C), a sealing member 1499 can be positioned between the first catheter 1002 and the second catheter 1102 for sealing the lumen 1004 of the first catheter 1002 when the second catheter 1102 is advanced distally past the sealing member.

In some embodiments, the first and second pressure sources 1040, 1140 (“pressure sources 1040, 1140”) are separate sources each configured to generate and store a vacuum for subsequent application to the first and second catheter subsystems 1000, 1100, respectively, as described in detail above with reference to FIGS. 1-10B. In other embodiments, one or both of the pressure sources 1040, 1140 can be configured to provide sustained negative pressure rather than a charge or burst of stored vacuum pressure. In yet other embodiments, one of the pressures sources 1040, 1140 can be omitted, or the pressure sources 1040, 1140 can be fluidly coupled and/or integrally formed.

FIG. 12 is a flow diagram of a process or method 1280 for operating a clot removal system including the assemblies 20 and 30 to remove clot material from within a blood vessel (e.g., a pulmonary blood vessel) of a human patient in accordance with the present technology. FIGS. 13A-13C are schematic illustrations of a distal portion of the assemblies 20, 30 during a clot removal procedure in accordance with the present technology. FIGS. 14A-14C are schematic side views of a distal portion of the assemblies 20, 30 during a clot removal procedure and including an optional sealing member in accordance with the present technology. Although some features of the method 1280 are described in the context of the embodiments shown in FIGS. 11 and 13A-14C for the sake of illustration, one skilled in the art will readily understand that the method 1280 can be carried out using other suitable systems and/or devices.

At block 1282, the method 1280 includes intravascularly positioning the first catheter 1002 within a human patient. FIG. 13A, for example, illustrates the first catheter 1002 after it has been advanced (e.g., as indicated by arrow A1) to a position within a blood vessel BV (e.g., a pulmonary blood vessel). More specifically, the first catheter 1002 can be advanced within the blood vessel BV until the distal portion 1003a of the first catheter 1002 is positioned proximal to clot material PE within the blood vessel BV. In some embodiments, the position of the distal portion 1003a of the first catheter 1002 relative to the clot material PE can be determined by activating the first valve 1006 and determining whether there is back-bleeding through the first valve 1006, as described in detail above. In the illustrated embodiment, the clot material PE is located within a branch (e.g., a reduced diameter portion) of the blood vessel BV. In some embodiments, access to the blood vessel BV can be achieved using an introducer and guidewire as described in detail above with reference to FIG. 8.

At block 1284, the method 1280 includes advancing the second catheter 1102 through the first catheter 1002 until the distal portion 1103a of the second catheter 1102 is positioned proximate to the clot material PE within the blood vessel BV (e.g., at a treatment site). To advance the second catheter 1102 through the first catheter 1002, the user can first insert the distal portion 1103a of the second catheter 1102 through the first valve 1006 before advancing the second catheter 1102 (e.g., as indicated by the arrow A1) through the lumen 1004 of the first catheter 1002. In some embodiments, the first valve 1006 can be actuated (e.g., by depressing one or more buttons) to open the lumen 1009 of the first valve 1006 so that the second catheter 1102 can be inserted therethrough. In some embodiments, the position of the distal portion 1103a of the second catheter 1102 relative to the clot material PE can be determined by activating the second valve 1106 and determining whether there is back-bleeding through the second valve 1106, as described in detail above. In other embodiments, the (smaller) second catheter 1102 can be intravascularly positioned proximate to the clot material PE before intravascularly positioning the (larger) first catheter 1002. In such embodiments, the second catheter 1102 can act as a guide or rail for guiding the advancement of the first catheter 1002 to the treatment site.

FIG. 13A illustrates the second catheter 1102 after it has been advanced through the first catheter 1002 and past a distal terminus of the first catheter 1002 to position a distal terminus of the second catheter 1102 proximate to a proximal portion of the clot material PE. In other embodiments, the distal terminus of the second catheter 1102 can be positioned at least partially within the clot material PE, or the distal terminus of the second catheter 1102 can be positioned distal of the clot material PE. In one aspect of the present technology, because the second catheter 1102 has a smaller cross-sectional dimension than the first catheter 1002, the second catheter 1102 can be advanced to narrower (e.g., more distal) treatment sites within the blood vessel BV. In the embodiment illustrated in FIG. 13A, for example, the first catheter 1002 may be too large to be positioned within the branch of the blood vessel BV, while the second catheter 1102 can be positioned within the branch proximate to or within the clot material PE.

At block 1286, the method 1280 includes coupling the second pressure source 1140 to the second catheter 1102 via the second fluid control device 1126. For example, any one or combination of the pressure sources described in detail above with reference to FIGS. 2-7 can be coupled to the second catheter 1102 via the second tubing subsystem 1120. Once the second pressure source 1140 is coupled to the second catheter 1102, (i) opening of the second fluid control device 1126 fluidly connects the second pressure source 1140 to the lumen 1104 of the second catheter 1102, and (ii) closing of the second fluid control device 1126 fluidly disconnects the second pressure source 1140 from the lumen 1104 of the second catheter 1102. In some embodiments, the method 1280 can further include coupling the first pressure source 1040 to the first catheter 1002 (e.g., via the first tubing subsystem 1020).

At block 1288, the method 1280 includes activating the second pressure source 1140 to generate a vacuum while the second fluid control device 1126 is closed. In particular, the second pressure source 1140 can be activated to build-up or pre-charge a vacuum for subsequent application to the second catheter 1102. In some embodiments, the first pressure source 1040 can also be activated to generate and store a vacuum for subsequent application to the first catheter 1002.

At block 1290, the method 1280 includes opening the second fluid control device 1126 to apply the vacuum stored in second pressure source 1140 to the lumen 1104 of the second catheter 1102. As shown in FIG. 13B, application of the vacuum causes suction (e.g., as indicated by arrow A2) that aspirates at least a portion of the clot material PE from the blood vessel BV and into the lumen 1104 of the second catheter 1102. In some embodiments, opening the second fluid control device 1126 instantaneously or nearly instantaneously generates suction at the distal portion 1103a of the second catheter 1102. In one aspect of the present technology, pre-charging or storing the vacuum before applying the vacuum to the lumen 1104 of the second catheter 1102 is expected to generate greater suction forces (and corresponding fluid flow velocities) at and/or near the distal portion 1103a of the second catheter 1102 compared to simply activating the second pressure source 1140 while it is fluidly connected to the second catheter 1102.

In some embodiments, where the first pressure source 1040 is also activated to generate and store a vacuum (e.g., at block 1288), the method 1280 can further comprise opening the first fluid control device 1026 to generate suction at the distal portion 1003a of the first catheter 1002. One skilled in the art will understand that the suction profile in the blood vessel BV can be selected or modified based on the characteristics of the pressure sources 1040, 1140 (e.g., volume, bore size, etc.) and the timing of the opening of the first and second fluid control devices 1026, 1126. For example, the first fluid control device 1026 can be opened at the same time as the second fluid control device 1126 to generate a combined and relatively large suction force in the blood vessel BV. In other embodiments, the first fluid control device 1026 can be opened after the second fluid control device 1126 to generate staggered or stepped suction forces in the blood vessel BV. For example, the first fluid control device 1026 can be opened after the second fluid control device 1126 to aspirate any of the clot material PE (i) remaining in the blood vessel BV after aspiration of the second catheter 1102 and/or (ii) stuck to or extending from the second catheter 1102. In other embodiments, the first pressure source 1040 can be a pump or other source for providing sustained negative pressure—rather than a built-up charge of negative pressure—and thus can generate sustained (e.g., constant) suction at the distal portion 1003a of the first catheter 1002. In some such embodiments, the first fluid control device 1026 can remain open during the clot removal procedure to provide sustained suction throughout the procedure.

In some embodiments, an interventional device can be delivered through the second catheter 1102 and used to engage the clot material PE before and/or after the vacuum is applied to the second catheter 1102. Specific details of suitable interventional devices and associated methods of use are disclosed in, for example, provisional U.S. patent application Ser. No. 16/258,344, filed Jan. 25, 2019, and titled “SINGLE INSERTION DELIVERY SYSTEM FOR TREATING EMBOLISM AND ASSOCIATED SYSTEMS AND METHODS,” which is incorporated herein by reference in its entirety.

At block 1292, the method 1280 includes retracting the second catheter 1102 proximally through the first catheter 1002. In some embodiments, multiple aspiration passes can be performed with the second catheter 1102 before retracting the second catheter 1102. In some embodiments, as shown in FIG. 13C, the first pressure source 1040 or another pressure source coupled to the first catheter 1002 can be activated to generate suction (e.g., as indicated by arrow A3) at the distal portion 1003a of the first catheter 1002 during retraction of the second catheter 1102. The suction can be constant or provided in one or more bursts, as described in detail above. In some embodiments, the second catheter 1102 can be fully withdrawn from the patient and disposed of or cleaned (e.g., flushed with a sterile liquid) for reuse.

Sometimes, the clot material PE is not fully pulled into the second catheter 1102 when the vacuum is applied to the second catheter 1102 (block 1290) and can therefore stick to or dangle from the distal portion 1103a of the second catheter 1102. FIG. 14A, for example, is an enlarged view of the distal portion of the assemblies 20, 30 shown in FIG. 13C and illustrating a portion of the clot material PE stuck to or dangling from the distal portion 1103a of the second catheter 1102. In the illustrated embodiment, an optional seal 1499 is disposed between the first and second catheters 1002, 1102 to facilitate the removal of such dangling clot material PE. More specifically, the seal 1499 (shown in cross-section) can be disposed between an outer surface of the second catheter 1102 and an inner surface of the first catheter 1002. The seal 1499 can be an O-ring, grommet, or other suitable component that fluidly disconnects the lumen 1004 of the first catheter 1002 from the blood vessel BV when the second catheter 1102 is positioned therethrough (e.g., when the distal terminus of the second catheter 1102 is positioned distally of the seal 1499).

FIGS. 14B and 14C are enlarged views of the distal portion of the assemblies 20, 30 and illustrating further retraction of the second catheter 1102 (and the dangling clot material PE) into the lumen 1004 of the first catheter 1002. In some embodiments, the first pressure source 1040 can be activated to charge a vacuum in the lumen 1004 of the first catheter 1002. For example, after the second catheter 1102 is advanced through the first catheter 1002 and past the seal 1499 (e.g., block 1284)—thereby sealing the lumen 1004 of the first catheter 1002—the operator can open the first fluid control device 1026 and activate the first pressure source 1040 to build up the vacuum in the lumen 1004 of the first catheter 1002. Referring to FIG. 14C, when the distal terminus of the second catheter 1102 is retracted proximally past the seal 1499, the lumen 1004 of the first catheter 1002 becomes fluidly connected to the blood vessel BV and the vacuum is instantaneously or nearly instantaneously released to generate suction (e.g., as indicated by arrows A4). In the illustrated embodiment, the suction acts to separate or otherwise dislodge the clot material PE from the second catheter 1102 and pull the clot material PE proximally through the lumen 1004 of the first catheter 1002. In this manner, a second burst of suction is automatically applied via the first catheter 1002 during retraction of the second catheter 1102. In one aspect of the present technology, the user does not need to take any additional step to release the vacuum stored in the first catheter 1002—as release is automatically triggered by retraction of the second catheter 1102.

At block 1294, the user can determine whether it is necessary or desirable to redeploy the second catheter 1102 or another catheter through the first catheter 1002 in order to remove any residual clot material PE that was not removed during the first aspiration pass and/or any clot material located elsewhere in the blood vessel BV (e.g., to initiate a second aspiration pass). In some embodiments, the operator can visualize the amount of clot material PE collected in the first pressure source 1040 and/or the second pressure source 1140 to at least partially determine whether another aspiration pass is needed. In other embodiments, the operator can rely on imaging (e.g., fluoroscopic imaging) of the blood vessel BV or other techniques known in the art to determine whether an additional aspiration pass is necessary or desirable.

If another pass is not needed (e.g., the clot material PE was adequately removed), the user can elect to fully withdraw the assemblies 20, 30 from the patient at block 1296. If clot material PE remains in the vessel, the method can return to block 1284. In particular, the same second catheter 1102 can be cleaned (e.g., flushed with saline) and advanced again through the first catheter 1002 until the distal portion 1103a of the second catheter 1102 is positioned proximate to the remaining clot material PE within the blood vessel BV. In some embodiments, a new second catheter 1102 can be used for each pass to reduce the likelihood of contamination (e.g., reintroduction of clot material PE). In some embodiments, the first catheter 1002 can be aspirated (e.g., via the first pressure source 1040) prior to redeployment of the second catheter 1102 to, for example, remove any clot material PE that may be in the first catheter 1002 to inhibit its reintroduction into the blood vessel BV as the second catheter 1102 is advanced therethrough during another pass. Once the desired amount of clot material PE has been removed from the patient, the assemblies 20, 30 may be fully withdrawn from the patient (block 1294).

In one aspect of the present technology, the method 1280 provides for an aspiration catheter to be deployed multiple times without requiring that the first catheter 1002 be removed after each deployment. Accordingly, the present technology allows for only a single insertion of a guide catheter during a procedure including multiple passes to remove clot material—increasing the speed of the procedure and reducing trauma to the patient since the guide catheter does not need to be reintroduced (e.g., advanced through the vasculature and past the heart) before each pass. Moreover, in certain embodiments, the present technology can enable the first catheter 1002 to be relocated to an alternate treatment site within the patient without removing the first catheter 1002 from the patient and, therefore, without reintroducing the first catheter 1002 through the heart. For example, the first catheter 1002 can be relocated to another treatment site within the lungs including a treatment site in the opposite lung. More specifically, (i) a dilator can be reintroduced into the first catheter 1002, (ii) the first catheter 1002 can be withdrawn into the main pulmonary artery, (iii) a guidewire can be redirected to the new treatment site, (iv) the first catheter 1002 can be advanced over the guidewire to the new treatment site, and (v) the dilator can be removed.

FIG. 15 is a flow diagram of another process or method 1580 for operating a clot removal system including the assemblies 20, 30 (FIG. 1) to remove clot material from within a blood vessel (e.g., a pulmonary blood vessel) of a human patient in accordance with the present technology. FIG. 16A is an enlarged side view of a distal portion of the first assembly 20, and FIGS. 16B-16E are side views of a distal portion of the assemblies 20, 30 during a clot removal procedure in which clot material clogs the first assembly 20 in accordance with the present technology. Although some features of the method 1580 are described in the context of the embodiments shown in FIGS. 11 and 16A-16E for the sake of illustration, one skilled in the art will readily understand that the method 1580 can be carried out using other suitable systems and/or devices.

Some features of the method 1580 are generally similar to those of the methods 880 and/or 1280 described in detail above with reference to FIGS. 8 and 12, respectively. For example, at block 1582 the method includes intravascularly positioning the first catheter 1002 of the first assembly 20 within a human patient. At block 1584, the method 1580 includes coupling the first pressure source 1040 to the first catheter 1002 via the first fluid control device 1026. For example, any one or combination of the pressure sources described in detail above with reference to FIGS. 2-7 can be coupled to the second catheter 1002 via the first tubing subsystem 1020. At block 1586, the method 1580 includes activating the first pressure source 1040 to generate a vacuum while the first fluid control device 1026 is closed. In particular, the first pressure source 1040 can be activated to build-up or pre-charge a vacuum for subsequent application to the first catheter 1002. At block 1588, the method 1580 includes opening the first fluid control device 1026 to apply the vacuum stored in the first pressure source 1040 to the lumen 1004 of the first catheter 1002. As described in detail above, opening the first fluid control device 1026 instantaneously or nearly instantaneously generates suction at the distal portion 1003a of the first catheter 1002.

Sometimes, however, clot material is not fully pulled into the first catheter 1002 and/or clogs the first catheter 1002 when the vacuum is applied to the first catheter 1002 (block 1588). FIG. 16A, for example, is an enlarged view of the distal portion of the first assembly 20 illustrating a portion of clot material PE that extends beyond from the distal portion 1003a of the first catheter 1002 and blocks/clogs the lumen 1004 of the first catheter 1002. As such, a portion of the clot material PE is not within the first catheter 1002. Accordingly, at block 1590, the method 1580 can include determining whether the first catheter 1002 is clogged. In some embodiments, the operator can determine that the first catheter 1002 is clogged based on the vacuum chamber of the first pressure source 1040 containing little to no clot material PE and blood. For example, since the clot material PE clogs the first catheter 1002, the vacuum chamber of the first pressure source 1040 cavitates when the first fluid control device 1026 is opened. If the first catheter 1002 is not clogged, the method 1580 can proceed to block 1598 and the first catheter 1002 can be withdrawn from the patient or the operator can perform another aspiration pass (e.g., as described in detail above with reference to blocks 808 and 810 of the method 800 shown in FIG. 8).

If the first catheter 1002 is clogged, the method 1580 can proceed to block 1592 which includes advancing the second catheter 1102 through the first catheter 1002 until the distal portion 1103a of the second catheter 1102 is positioned in or proximate to the clogging clot material PE. For example, FIG. 16B illustrates the second catheter 1102 after it has been advanced to a position within the first catheter 1002 in which the distal terminus of the second catheter 1102 is at or proximate to the clogging clot material PE. To advance the second catheter 1102 through the first catheter 1002, the user can first insert the distal portion 1103a of the second catheter 1102 through the first valve 1006 (FIG. 11) before advancing the second catheter 1102 through the lumen 1004 of the first catheter 1002.

At block 1594, the method 1580 includes activating the second pressure source 1140 (FIG. 11) coupled to the second catheter 1102. More specifically, the second pressure source 1140 (e.g., any one or combination of the pressure sources described in detail above with reference to FIGS. 2-7) can be coupled to the second catheter 1102 via the second fluid control device 1126 (FIG. 11), and the second pressure source 1140 can be activated to build-up or pre-charge a vacuum while the second fluid control device 1126 is closed. The second fluid control device 1126 can then be actuated to apply the vacuum stored in the second pressure source 1140 to the lumen 1104 of the second catheter 1102. In other embodiments, the second pressure source 1140 can simply provide a sustained vacuum rather than an instantaneous release of vacuum. That is, in some embodiments the second pressure source 1140 is not pre-charged with a vacuum.

Applying the vacuum to second catheter 1102 can aspirate at least a portion of the clogging clot material PE into the second catheter 1102 and/or suck the clot material PE against the distal terminus of the second catheter 1102. FIG. 16C, for example, illustrates a portion of the clot material PE stuck to or extending from the distal portion 1103a of the second catheter 1102 after aspirating the second catheter 1102. In the embodiment illustrated in FIG. 16C, the added vacuum pressure generated through the second catheter 1102 is still not enough to break apart the clot material PE such that it can be fully aspirated through the first and/or second catheters 1002, 1102. That is, the clot material PE clogs the lumen 1004 of the first catheter 1002. In other embodiments, the added vacuum pressure from the second pressure source 1140 is sufficient to break apart the clot material PE such that it is aspirated into, for example, the vacuum chambers of the first and/or second pressure sources 1040, 1140.

At block 1596, the method can include retracting the second catheter 1102 and the clot material PE through the lumen 1004 of the first catheter 1002. For example, FIG. 16D illustrates retracting the second catheter 1102, which in turn retracts the attached clot material PE, through the lumen 1004 of the first catheter 1002. In some embodiments, the second catheter 1102 and clot material PE can be fully withdrawn through the first catheter 1002. In other embodiments, retracting the clot material PE through the first catheter 1002 causes the clot material PE to break apart and be aspirated into the vacuum chambers of the first and/or second pressure sources 1040, 1140. FIG. 16E, for example, illustrates the clot material PE breaking apart as the vacuum of the first and/or second pressure sources 1040, 1140 is instantaneously or nearly instantaneously released to suck the clot material PE proximally (e.g., as indicated by arrows A5).

At block 1598, the first and second catheters 1002, 1102 can be withdrawn from the patient or the operator can perform another aspiration pass using one or both of the first and second catheters 1002, 1102.

In one aspect of the present technology, the method 1580 removes clot material even when a first aspiration pass clogs the first catheter 1002. More particularly, the second catheter 1102 can be used to remove clogged clot material PE without requiring the first catheter 1002 and the clogged clot material PE to be withdrawn through the blood vessel BV.

V. Additional Selected Embodiments of Clot Removal Systems and Associated Methods of Clot Removal

From the foregoing, it will be appreciated that specific embodiments of the present technology have been described herein for purposes of illustration, but that various modifications may be made without deviating from the scope of the present technology. For example, in many of the embodiments described above, stored vacuum pressure can be used to aspirate or suck clot material from a blood vessel and into a catheter without the need to engage an interventional device with the clot material. However, one skilled in the art will understand that the aspiration devices and techniques disclosed herein can be used in conjunction with any suitable interventional device and/or during a clot removal procedure utilizing an interventional device. In some embodiments, for example, a clot removal system can be configured to apply stored vacuum pressure to a guide catheter to generate a burst of suction while an interventional device is retracted into and/or through the guide catheter.

FIG. 17, for example, is a partially schematic view of a clot removal system 1700 (“system 1700”) configured in accordance with the present technology. The system 1700 includes some features generally similar to the features of the clot removal system described in detail above with reference to FIG. 1. For example, the system 1700 includes a catheter or sheath 1702 comprising an elongated shaft, and a valve 1706 coupled to a proximal portion of the sheath 1702. The valve 1706 has a side port 1708 that fluidly couples a lumen of the sheath 1702 to a tubing subsystem 1720 and a pressure source 1740 (shown schematically). A fluid control device 1726 (e.g., a stopcock or clamp; shown schematically) is operable to fluidly disconnect or connect the pressure source 1740 from/to the lumen of the sheath 1702. The pressure source 1740 can be any suitable pressure source for generating and storing vacuum pressure, as described in detail above.

In the illustrated embodiment, the system 1700 further includes (i) a self-expanding (e.g., mesh) funnel 1780 coupled to a proximal portion of the sheath 1702 and (ii) an interventional device (e.g., a thrombus extraction device) 1790. In the illustrated embodiment, the interventional device 1790 includes an expandable coring element (e.g., a first portion) 1792 coupled to an expandable cylindrical element (e.g., a second portion) 1794. In some embodiments, the interventional device 1790 is configured to self-expand from a compressed delivery state to an expanded deployed state. The interventional device 1790 is shown in the deployed state in FIG. 17. An elongated shaft 1782 and/or one or more shafts positioned within the elongated shaft 1782 (e.g., an intermediate shaft 1884 and an inner shaft 1886 as shown in FIGS. 18E and 18F, respectively) are coupled to the interventional device 1790 and configured to retract, advance, and/or manipulate (e.g., move between the delivery and deployed states) the interventional device 1790. In some embodiments, the system 1700 can be generally the same as or similar to any of the clot removal systems disclosed in U.S. Patent Application Publication No. 2018/0193043, filed Apr. 26, 2017, and titled “DEVICES AND METHODS FOR TREATING VASCULAR OCCLUSION,” which is incorporated herein by reference in its entirety.

In the illustrated embodiment, the system 1700 is shown intravascularly positioned within a blood vessel BV of a human patient and proximate to clot material DV (e.g., a deep vein thrombus) within the blood vessel BV. Specifically, FIG. 17 shows the system 1700 after (i) advancing the sheath 1702 to a position proximate to a proximal portion 1785b of the clot material DV, (ii) deploying the funnel 1780, (iii) deploying the interventional device 1790 from the sheath 1702 (e.g., by advancing the interventional device 1790 through the valve 1706 and the sheath 1702 to a position distal of a distal portion 1785a of the clot material DV), and (iv) expanding the interventional device 1790 from the compressed delivery state to the deployed state.

FIGS. 18A-18H are enlarged views of a distal portion of the system 1700 during a clot removal procedure in accordance with the present technology. In general, FIGS. 18A-18H illustrate the proximal retraction of the interventional device 1790 through the clot material DV to capture at least a portion of the clot material DV, and the subsequent joint retraction of the interventional device 1790 and the captured clot material DV into the funnel 1780 and the sheath 1702. In one aspect of the present technology, charged vacuum pressure generated in the vacuum source 1740 can be applied to the sheath 1702 at one or more times during the illustrated process to generate suction for aspirating the captured clot material DV through the sheath 1702 and/or to inhibit clogging of the sheath 1702.

Referring first to FIG. 18A, proximal retraction of the interventional device 1790 causes the coring element 1792 to separate and/or core the distal end portion 1785a of the clot material DV from the walls W of the blood vessel BV. As shown in FIG. 18B, continued proximal retraction of the interventional device 1790 through the clot material DV causes the cylindrical element 1794 to capture the distal end portion 1785a of the clot material therein. FIGS. 18C-18E illustrate further proximal retraction of the interventional device 1790 which causes further separation, coring, and/or capture of the clot material DV. As seen in FIG. 18E, the proximal end portion 1785b of the clot material DV is cored and captured as the interventional device 1790 is proximally retracted toward the funnel 1780 and the sheath 1702. As further shown in FIG. 18E, a first radiopaque marker 1887a can be positioned on a distal end portion of the inner shaft 1884 and a second radiopaque marker 1887b can be positioned on a distal end portion of the sheath 1702.

In some embodiments, as shown in FIG. 18F, the interventional device 1790 can be proximally retracted until a portion of the coring element 1792 is contained (e.g., positioned) within the funnel 1780. More specifically, the interventional device 1790 can be proximally retracted until a mouth 1895 of the coring element 1792 is contained within the funnel 1780. In some embodiments, the containment of the mouth 1895 within the funnel 1780 can be fluoroscopically verified by visualization of the radiopaque markers 1887 (FIG. 18E). In some embodiments, for example, the mouth 1895 can be determined as wholly contained within the funnel 1780 via fluoroscopic monitoring based on the alignment of the distal end portion of the inner shaft 1884 (e.g., the first radiopaque marker 1885a) relative to the distal end portion of the sheath 1702 (e.g., the second radiopaque marker 1885b). In some embodiments, when the mouth 1895 of the coring element 1792 is positioned within the funnel 1780, the interventional device 1790 can be moved or transformed from the expanded deployed state to the compressed delivery state to compress and secure the clot material DV captured by the interventional device 1790. In some embodiments, for example, the intermediate shaft 1884 can be unlocked and/or decoupled from the inner shaft 1886 (e.g., via user actuation of a plunger or other device) such that the inner shaft 1886 can be advanced distally relative to the intermediate shaft 1884 to collapse or compress the interventional device 1790.

After the interventional device 1790 has been collapsed, the interventional device 1790 can be proximally retracted through the funnel 1780 and into the sheath 1702 as depicted in FIG. 18G. As shown in FIG. 18H, the interventional device 1790 can continue to be proximally retracted until the interventional device 1790 and the captured clot material DV are fully contained within the sheath 1702. In some embodiments, the interventional device 1790 and the captured clot material DV can then be withdrawn through the sheath 1702 and the valve 1706 (FIG. 17), and from the patient's body.

In some embodiments, the collapse of the interventional device 1790 and/or the retraction of the interventional device 1790 into the funnel 1780 and/or the sheath 1702 can result in one or more portions of the clot material DV breaking away from the clot material DV contained in the interventional device 1790. For example, all or a portion of the captured clot material DV can be extruded through pores of the (e.g., mesh) cylindrical element 1794 as the interventional device 1790 collapses. In some embodiments, any such clot material can be captured by the funnel 1780. Referring to FIG. 17, in some embodiments, the pressure source 1740 can be activated to charge a vacuum, and the fluid control device 1726 can subsequently be opened to apply the charged vacuum to the sheath 1702 (as described in detail above). The vacuum can be applied to the sheath 1702 at any point during retraction of the interventional device 1790. As shown in FIGS. 18G and 18H, application of the vacuum can generate instantaneous or nearly instantaneous suction (e.g., as indicated by arrows A6) at the distal end portion the sheath 1702 that can aspirate the extruded portions and/or other portions of the clot material DV into and/or through the sheath 1702. In particular, the generated suction can aspirate some or all of the clot material DV captured by the funnel 1780. Moreover, in some embodiments, application of a vacuum from the pressure source 1740 can facilitate smooth retraction of the captured clot material DV through the sheath 1702. For example, a burst of suction generated by application of the vacuum can help inhibit clogging of the sheath 1702, and/or help resolve (e.g., break apart) a clog formed in the sheath 1702 during retraction.

VI. Selected Embodiments of Clot Removal Systems Having Filters and Associated Methods of Clot Removal

The systems and methods for clot removal described herein can include applying a pre-charged vacuum to generate suction for aspirating clot removal from the blood vessel of a patient. In one aspect of the present technology, aspiration of the clot material also aspirates blood from the patient. It can be advantageous to reintroduce the aspirated blood to the patient to lessen the trauma to the patient—especially where the removal procedure may comprise multiple aspiration passes that can together withdraw a significant amount of blood. However, the aspirated blood is often mixed with clot material and is therefore not suitable for reintroduction into the patient. FIGS. 19-20E illustrate various devices for filtering aspirated blood from removed clot material to reintroduce the aspirated blood into the patient without reintroducing a significant amount of clot material.

For example, FIG. 19 is a perspective side view of a pressure source 1900 for filtering blood from aspirated clot material during a clot removal procedure configured in accordance with the present technology. The pressure source 1900 is generally similar to the pressure source 400 described in detail above with reference to FIGS. 4A-4C. For example, the pressure source 1900 includes the secondary syringe 460 (“syringe 460”) and the first and second one-way valves 470 and 472. However, the secondary syringe 460 is coupled to a canister 1940 rather than the primary syringe 340 (FIGS. 4A-4C). The canister 1940 includes a tip (obscured) coupled to the adaptor 350 and is configured to be removably positioned within the connector 128 of the tubing subsystem 120 (FIG. 1) to fluidly couple the canister 1940 to the tubing subsystem 120. Because the canister 1940 does not include a plunger or other component for changing a volume thereof, the syringe 460 is the only vacuum source for evacuating the canister 1940 (e.g., via repeated cycling of the secondary syringe 460).

In the illustrated embodiment, the canister 1940 further includes a filter 1942. The canister 1940 is shown as transparent in FIG. 19 for the sake of clarity. The filter 1942 is coupled to and/or covers a removable end cap 1944 having a blood separation port 1946. In operation, when blood and clot material are aspirated into the canister 1940 (e.g., via any of the methods described in detail above), the filter 1942 separates the blood from the clot material within the canister 1940. The filtered blood can be removed via the blood separation port 1946. For example, a syringe (not shown) or other device can be fluidly coupled to the blood separation port 1946 and used to draw the blood through the filter 1942 and out of the canister 1940. The filtered blood can then be reintroduced to the patient via, for example, the fluid control device 126 and/or the connector 128 of the tubing subsystem 120. Once the blood is removed from the canister 1940, the end cap 1944 can be removed from the canister 1940 (e.g., by unscrewing the end cap 1944 from the body of the canister 1940) for removing the captured clot material. In some embodiments, the filter 1942 is attached to the end cap 1944 such that removing the end cap 1944 removes the filter 1942 and permits clot material to be dumped, scooped, or otherwise removed from the canister 1940.

FIGS. 20A-20E illustrate a filter device 2050 for filtering blood from aspirated clot material during a clot removal procedure configured in accordance with the present technology. The filter device 2050 is configured as an in-line filter for use with, for example, one or more of the pressure sources described in detail above with reference to FIGS. 2-7. For example, FIG. 20A is a partially-exploded side view of the filter device 2050 and the pressure source 340 (FIGS. 3A-3D). In the illustrated embodiment, the filter device 2050 comprises a filter portion 2060 that is removably positionable within a barrel portion 2070. In the illustrated embodiment, the barrel portion 2070 includes a barrel 2072 that defines a chamber 2074, and a large bore tip 2076 configured to fluidly couple the chamber 2074 to external components, such as the tubing subsystem 120 (e.g., as shown in FIG. 20C). The filter portion 2060 includes a seal 2062 configured to engage (i) an interior surface of the barrel 2072 when the filter portion 2060 is positioned within the chamber 2074 of the barrel portion 2070 and (ii) an exterior surface of the syringe 340 (e.g., an exterior surface of the barrel 344) when the syringe 340 is inserted into the filter device 2050. In other embodiments, the filter portion 2060 can be permanently attached to or integrally formed with the barrel portion 2070. The filter portion 2060 further includes a filter (e.g., a mesh) 2064 configured (e.g., sized and shaped) to inhibit clot material from passing therethrough. In some embodiments, the filter 2064 can be configured to inhibit clots larger than about 100 μm (e.g., larger than about 110 μm) from passing therethrough.

FIG. 20B is a perspective side view of the syringe 340 coupled to the filter device 2050. The barrel 2072 of the barrel portion 2070 is shown as transparent in FIG. 20B (and FIGS. 20C-20E) for the sake of clarity. In the illustrated embodiment, the seal 2062 is positioned between the exterior surface of the barrel 344 of the syringe 340 and the interior surface of the barrel 2072 of the barrel portion 2070. The filter 2064 is positioned around (e.g., covers) the tip 347 of the syringe 340 to inhibit clot material from entering the barrel 344 of the syringe 340 during operation.

FIG. 20C is a side view of the filter device 2050 and syringe 340 coupled to the tubing subsystem 120 of the assembly 10. More specifically, the tip 2076 can be inserted into the connector 128 of the tubing subsystem 120 as described in detail above. When the filter device 2050 and the syringe 340 are coupled to the tubing subsystem 120, the filter device 2050 is positioned in-line (e.g., in series) with the syringe 340. In the embodiment illustrated in FIG. 20C, the plunger 342 of the syringe 340 has been withdrawn to generate negative pressure in the combined volume of the barrels 2072 and 344. As described in detail above, opening the fluid control device 126 nearly instantaneously applies the negative pressure to the catheter 102 to generate suction therein. When clot material and blood are aspirated through the catheter 102 and the tubing subsystem 120, the filter portion 2060 inhibits the clot material from entering the barrel 344 of the syringe 340. Thus, aspirated blood is collected in the barrel 344 of the syringe 340 while the aspirated clot material is collected in the barrel 2072 of the barrel portion 2070 of the filter device 2050. In this manner, clot material and blood can be separated during aspiration.

In one aspect of the present technology, separating the blood from the clot material such that the blood is within the syringe 340 permits the blood to be easily reintroduced to the patient. For example, FIGS. 20D and 20E are side views of the syringe 340 coupled to the tubing subsystem 120 of the assembly 10 for reintroducing blood to a patient. In some embodiments, as shown in FIG. 20D, the syringe 340 can be decoupled from the filter device 2050 and directly coupled to the connector 128. With the fluid control device 126 in an open position, the blood can then be reintroduced to the patient through the assembly 10 by depressing the plunger 342 of the syringe 340. In some embodiments, as shown in FIG. 20E, the syringe 340 can be decoupled from the filter device 2050 and directly coupled to a port on the fluid control device 126. With the fluid control device 126 in a closed position, the blood can then be reintroduced to the patient through the assembly 10 by depressing the plunger 342 of the syringe 340. Referring to FIGS. 20A-20E together, after or before reintroducing filtered blood to the patient, the filter portion 2060 of the filter device 2050 can be removed from the barrel portion 2070 so that the collected clot material can be removed and the filter device 2050 cleaned. In some embodiments, the filter device 2050 and a coupled pressure source can be used to filter blood from clot material after—as opposed to during—an aspiration pass. For example, the filter device 2050 and coupled pressure source could be used to withdraw blood and clot material collected in the canister 1940 of the pressure source 1900 (e.g., where the canister 1940 does not include the filter 1942).

FIGS. 21A and 21B illustrate a filter device 2150 for filtering blood from aspirated clot material during a clot removal procedure configured in accordance with the present technology. The filter device 2150 is configured for use with, for example, one or more of the pressure sources described in detail above with reference to FIGS. 2-7. For example, FIG. 21A is a partially-exploded side view of the filter device 2150 and the pressure source 340 (FIGS. 3A-3D). In the illustrated embodiment, the filter device 2150 includes a housing 2152 defining a chamber 2154, a filter 2156 configured to be positioned within the housing 2152, and a cap assembly 2160 configured to be releasably coupled to the housing 2152 (e.g., via a threaded connection, snap-fit connection, etc.). In some embodiments, the filter 2156 can have a porosity of between about 50-200 microns.

The housing 2152 can include a port 2153 configured to be removably, fluidly coupled to the pressure source 340 via a tubing subsystem 2120. In the illustrated embodiment, the tubing subsystem 2120 includes tubing sections 2124 (individually labeled as a first tubing section 2124a and a second tubing section 2124b), a fluid control device 2126 (e.g., a valve, stop cock, clamp, etc.), and a connector 2128 (e.g., a large bore connector) for fluidly coupling the tubing subsystem 2120 to the pressure source 340. In the illustrated embodiment, the cap assembly 2160 includes a fluid connector 2162 (e.g., a standard Luer or large bore connector) configured to be connected to a receiving/reinfusion syringe 2170 via, for example, a tubing section 2164. In some embodiments, the cap assembly 2160 can include a valve (e.g., a one-way valve, a check valve, etc.) that provides for one-way fluid flow through filter assembly 2150.

In operation, during a clot removal procedure, the pressure source 340 can be decoupled from the connector 128 (FIG. 1) after an aspiration pass and when the pressure source 340 is full of blood and clot material. After connecting the filter device 2150 to the receiving syringe 2170, the pressure source 340 can be coupled to the filter device 2150. For example, FIG. 21B is a perspective side view of the filter device 2150 coupled to (i) the pressure source 340 via the tubing subsystem 2120 and (ii) the reinfusion syringe 2170 via the tubing section 2164. More specifically, referring to FIGS. 21A and 21B together, the tip 347 of the pressure source 340 can be coupled to the connector 2128 of the tubing subsystem 2120, and a tip 2172 of the reinfusion syringe 2170 can be coupled to the tubing section 2164. In other embodiments, the filter device 2150 can be coupled to the pressure source 340 and/or the reinfusion syringe 2170 in other manners (e.g., directly such that the all or part of the tubing subsystem 120 is omitted). Alternatively, the filter device 2150 can be directly attached to the side port 108 (FIG. 1), an IV line (not shown), or another suitable connection point for reintroducing blood to the patient,

After coupling the pressure source 340 to the filter device 2150, the fluid control device 2128 can be opened to fluidly connect the pressure source 340 to the filter device 2150. Then, the operator can depress the plunger 342 of the pressure source 340 to drive the blood and clot material from the pressure source 340 into and/or through the filter device 2150. The filter 2156 of the filter device 2150 filters the blood from the clot material such that the blood flows into the reinfusion syringe 2170 and the clot material remains in the chamber 2154 of the filter device 2150. For example, as shown in FIG. 21B, blood B fills the reinfusion syringe 2170 and clot material PE remains within the chamber 2154 of the filter device 2150 after depressing the plunger 342 of the pressure source 340 in the direction indicated by the arrow H.

Next, the reinfusion syringe 2170 can be decoupled from the filter device 2150 so that the blood B can be reintroduced to the patient. For example, the reinfusion syringe 2170 could be directly coupled to a port on the fluid control device 126 (FIG. 1). The cap assembly 2160 can be decoupled from the housing 2152 of the filter device 2150 to, for example, permit an operator to remove the clot material PE collected in the housing 2152 and thereby clean and prepare the filter device 2150 for another use.

FIG. 22 is a partially-exploded side view of a filter device 2250 for filtering blood from aspirated clot material during a clot removal procedure configured in accordance with the present technology. The filter device 2250 is configured for use with, for example, one or more of the pressure sources described in detail above with reference to FIGS. 2-7. In general, the filter device 2250 is generally similar to the filter device 2150 described in detail with reference to FIGS. 21A and 21B. For example, the filter device 2250 includes a housing 2252 defining a chamber 2254, a filter 2256 configured to be positioned within the housing 2252, and a cap assembly 2260 configured to be releasably coupled to the housing 2252. However, in the illustrated embodiment the filter device 2250 includes a port 2253 that is directly connected to a connector 2228 configured to be coupled to a pressure source (e.g., the pressure source 340 shown in FIGS. 3A-3D). The cap assembly 2260 includes a fluid connector 2162 (e.g., a standard Luer or large bore connector) configured to be connected to a reinfusion syringe, a sheath, an IV line, etc., (not shown). In some embodiments, the fluid connector 2262 is angled relative to the filter 2260 and/or the housing 2252. For example, the fluid connector 2262 is formed to have an approximately right angle in FIG. 22. In one aspect of the present technology, this arrangement makes the filter device more ergonomic during use.

FIG. 23 is a partially-exploded side view of a filter device 2350 for filtering blood from aspirated clot material during a clot removal procedure configured in accordance with the present technology. The filter device 2350 is configured for use with, for example, one or more of the pressure sources described in detail above with reference to FIGS. 2-7. The filter device 2350 is generally identical to the filter device 2250 described in detail with reference to FIG. 22—including, for example, the housing 2252 (“a first housing 2252”), the filter 2256 (“a first filter 2256”), and the cap assembly 2260 including the fluid connector 2262 (“a first fluid connector 2262”). However, in the illustrated embodiment a second housing 2382 and a second filter 2386 are fluidly connected to the fluid connector 2262. The second housing 2382 includes a second fluid connector 2384 that can be fluidly connected to a reinfusion syringe, a sheath, an IV line, etc., (not shown). The second filter 2386 is configured to provide a second stage of filtration. For example, in some embodiments the first filter 2256 has a larger porosity than the second filter 2386. For example, the first filter 2256 can have a porosity of between about 50-200 microns and the second filter 2386 can have a porosity of between about 50-170 microns.

In general, one skilled in the art will understand that the various embodiments of filter devices disclosed herein may have different components or combinations of components. For example, the filter devices 2050, 2150, 2250, and/or 2350 (“the filter devices”) could be utilized with any of several different pressure sources other than the syringe 340 (e.g., those shown in FIGS. 2 and 4-7). In some embodiments, the filter devices can be formed as a component of the tubing subsystem 120 (FIG. 1). Moreover, the filter devices can include any number of filters and/or housings to provide any number of filtration stages.

CONCLUSION

The above detailed descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.

From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.

Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.

Claims

1. A method for the treatment of clot material within a vasculature of a patient, the method comprising: positioning an aspiration catheter at least partially within the vasculature proximate to the clot material;fluidly coupling a first chamber to an aspiration pump;fluidly coupling the first chamber to a second chamber distal of the first chamber;positioning a filter within the second chamber;selectively fluidly coupling the aspiration catheter to the second chamber via a user-actuatable valve positioned between the second chamber and the aspiration catheter;with the valve closed to inhibit fluid flow from the aspiration catheter to the second chamber, generating negative pressure in the first and second chambers;after generating the negative pressure, opening the valve via a user actuation such that fluid flow at least partially from the second chamber into the first chamber causes rapid aspiration of blood and at least a portion of the clot material into the second chamber, wherein the filter is configured to filter the blood from the portion of the clot material; andreintroducing the filtered blood into the vasculature of the patient.
2. The method of claim 1 wherein reintroducing the filtered blood into the patient includes directing the filtered blood distally through the aspiration catheter.
3. The method of claim 1 wherein the clot material comprises a pulmonary embolism.
4. The method of claim 1 wherein the clot material comprises a deep vein thrombus.
5. The method of claim 1 wherein the method further comprises selectively providing fluid access to a lumen of the aspiration catheter via a hemostasis valve fluidly coupled to the lumen of the aspiration catheter.
6. The method of claim 5 wherein the second chamber, the aspiration catheter, and the hemostasis valve form a coupled assembly.
7. The method of claim 6 wherein the second chamber is removably carried by the coupled assembly.
8. The method of claim 5 wherein the method further comprises advancing a second catheter at least partially through the hemostasis valve and the lumen of the aspiration catheter.
9. The method of claim 8 wherein advancing the second catheter at least partially through the hemostasis valve includes sliding the second catheter through a lumen of a tubular member of the hemostasis valve, wherein the hemostasis valve further comprises a filament extending at least partially around the tubular member, and wherein the filament is moveable between (a) a first position wherein the filament circumferentially constricts the lumen to create a seal around the second catheter and (b) a second position wherein the filament is moved to at least partially open the lumen.
10. The method of claim 1 wherein the second chamber is removably coupled between the aspiration pump and the aspiration catheter.
11. The method of claim 1 wherein the first chamber has a first volume, and wherein the second chamber has a second volume smaller than the first volume.
12. The method of claim 1 wherein reintroducing the filtered blood into the patient includes directing the filtered blood distally through a catheter separate from the aspiration catheter.
13. The method of claim 1 wherein the method further comprises removing the filter from within the second chamber; andclearing the portion of the clot material from within the second chamber.
14. The method of claim 1 wherein positioning the aspiration catheter at least partially within the vasculature proximate to the clot material includes positioning a distal end portion of the aspiration catheter proximal to the clot material.
15. The method of claim 1 wherein the clot material comprises a pulmonary embolism or deep vein thrombosis.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 18/167,757, filed Feb. 10, 2023, which is a continuation of U.S. patent application Ser. No. 17/976,711, filed Oct. 28, 2022, which is a continuation of U.S. patent application Ser. No. 17/865,315, filed Jul. 14, 2022, which is a continuation of U.S. patent application Ser. No. 16/536,185, filed Aug. 8, 2019, and issued as U.S. Pat. No. 11,559,382, which claims the benefit of U.S. Provisional Patent Application No. 62/718,269, filed on Aug. 13, 2018, and U.S. Provisional Patent Application No. 62/718,248, filed on Aug. 13, 2018, each of which is herein incorporated by reference in its entirety.

US Referenced Citations (913)

Number	Name	Date	Kind
1101890	Tunstead	Jun 1914	A
2784717	Thompson	Mar 1957	A
2846179	Monckton	Aug 1958	A
2955592	Maclean	Oct 1960	A
3088363	Sparks	May 1963	A
3197173	Taubenheim	Jul 1965	A
3416531	Edwards	Dec 1968	A
3435826	Fogarty	Apr 1969	A
3438607	Williams et al.	Apr 1969	A
3515137	Santomieri	Jun 1970	A
3675657	Gauthier	Jul 1972	A
3785380	Brumfield	Jan 1974	A
3860006	Patel	Jan 1975	A
3892161	Sokol	Jul 1975	A
3923065	Nozick et al.	Dec 1975	A
4030503	Clark, III	Jun 1977	A
4034642	Iannucci et al.	Jul 1977	A
4222380	Terayama	Sep 1980	A
4243040	Beecher	Jan 1981	A
4287808	Leonard et al.	Sep 1981	A
4324262	Hall	Apr 1982	A
4393872	Reznik et al.	Jul 1983	A
4401107	Harber et al.	Aug 1983	A
4469100	Hardwick	Sep 1984	A
4523738	Raftis et al.	Jun 1985	A
4551862	Haber	Nov 1985	A
4604094	Shook	Aug 1986	A
4611594	Grayhack et al.	Sep 1986	A
4634421	Hegemann	Jan 1987	A
4643184	Mobin-Uddin	Feb 1987	A
4646736	Auth et al.	Mar 1987	A
4650466	Luther	Mar 1987	A
4776337	Palmaz	Oct 1988	A
4790812	Hawkins, Jr. et al.	Dec 1988	A
4863440	Chin et al.	Sep 1989	A
4870953	DonMichael et al.	Oct 1989	A
4883458	Shiber	Nov 1989	A
4886062	Wiktor	Dec 1989	A
4890611	Monfort et al.	Jan 1990	A
4898575	Fischell et al.	Feb 1990	A
4946440	Hall	Aug 1990	A
4960259	Sunnanvader et al.	Oct 1990	A
4978341	Niederhauser	Dec 1990	A
4981478	Evard et al.	Jan 1991	A
5030201	Palestrant	Jul 1991	A
5059178	Ya	Oct 1991	A
5100423	Fearnot	Mar 1992	A
5127626	Hilal et al.	Jul 1992	A
5129910	Phan et al.	Jul 1992	A
5135484	Wright	Aug 1992	A
5154724	Andrews	Oct 1992	A
5158533	Strauss et al.	Oct 1992	A
5158564	Schnepp-Pesch et al.	Oct 1992	A
5192274	Bierman	Mar 1993	A
5192286	Phan et al.	Mar 1993	A
5192290	Hilal	Mar 1993	A
5197485	Grooters	Mar 1993	A
5234403	Yoda et al.	Aug 1993	A
5242461	Kortenbach et al.	Sep 1993	A
5244619	Burnham	Sep 1993	A
5323514	Masuda et al.	Jun 1994	A
5329923	Lundquist	Jul 1994	A
5360417	Gravener et al.	Nov 1994	A
5364345	Lowery et al.	Nov 1994	A
5376101	Green et al.	Dec 1994	A
5383887	Nadal	Jan 1995	A
5389100	Bacich et al.	Feb 1995	A
5391152	Patterson et al.	Feb 1995	A
5419774	Willard et al.	May 1995	A
5421824	Clement et al.	Jun 1995	A
5443443	Shiber	Aug 1995	A
5456667	Ham et al.	Oct 1995	A
5476450	Ruggio	Dec 1995	A
5484418	Quiachon et al.	Jan 1996	A
5490859	Mische et al.	Feb 1996	A
5496365	Sgro	Mar 1996	A
5527326	Hermann et al.	Jun 1996	A
5549626	Miller et al.	Aug 1996	A
5591137	Stevens	Jan 1997	A
5639276	Weinstock et al.	Jun 1997	A
5653684	Laptewicz et al.	Aug 1997	A
5662703	Yurek et al.	Sep 1997	A
5746758	Nordgren et al.	May 1998	A
5749858	Cramer	May 1998	A
5769816	Barbut et al.	Jun 1998	A
5782817	Franzel et al.	Jul 1998	A
5800457	Gelbfish	Sep 1998	A
5827229	Auth et al.	Oct 1998	A
5846251	Hart	Dec 1998	A
5860938	Lafontaine et al.	Jan 1999	A
5873866	Kondo et al.	Feb 1999	A
5873882	Straub et al.	Feb 1999	A
5876414	Straub	Mar 1999	A
5895406	Gray et al.	Apr 1999	A
5908435	Samuels	Jun 1999	A
5911710	Barry et al.	Jun 1999	A
5911728	Sepetka et al.	Jun 1999	A
5911733	Parodi	Jun 1999	A
5911754	Kanesaka et al.	Jun 1999	A
5941869	Patterson et al.	Aug 1999	A
5947985	Imram	Sep 1999	A
5951539	Nita et al.	Sep 1999	A
5954737	Lee	Sep 1999	A
5971938	Hart et al.	Oct 1999	A
5971958	Zhang	Oct 1999	A
5972019	Engelson et al.	Oct 1999	A
5974938	Lloyd	Nov 1999	A
5989233	Yoon	Nov 1999	A
5993483	Gianotti	Nov 1999	A
6017335	Burnham	Jan 2000	A
6030397	Moneti et al.	Feb 2000	A
6059745	Gelbfish	May 2000	A
6059814	Ladd	May 2000	A
6066158	Engelson et al.	May 2000	A
6068645	Tu	May 2000	A
6126635	Simpson et al.	Oct 2000	A
6142987	Tsugita	Nov 2000	A
6146396	Konya et al.	Nov 2000	A
6146403	St. Germain	Nov 2000	A
6152144	Lesh et al.	Nov 2000	A
6152946	Broome et al.	Nov 2000	A
6156055	Ravenscroft	Dec 2000	A
6159230	Samuels	Dec 2000	A
6165196	Stack et al.	Dec 2000	A
6168579	Tsugita	Jan 2001	B1
6179859	Bates et al.	Jan 2001	B1
6221006	Dubrul et al.	Apr 2001	B1
6228060	Howell	May 2001	B1
6238412	Dubrul et al.	May 2001	B1
6245078	Ouchi	Jun 2001	B1
6245089	Daniel et al.	Jun 2001	B1
6254571	Hart	Jul 2001	B1
6258115	Dubrul	Jul 2001	B1
6264663	Cano	Jul 2001	B1
6306163	Fitz	Oct 2001	B1
6322572	Lee	Nov 2001	B1
6350271	Kurz et al.	Feb 2002	B1
6361545	Macoviak et al.	Mar 2002	B1
6364895	Greenhalgh	Apr 2002	B1
6368339	Amplatz	Apr 2002	B1
6383205	Samson et al.	May 2002	B1
6402771	Palmer et al.	Jun 2002	B1
6413235	Parodi	Jul 2002	B1
6423032	Parodi	Jul 2002	B2
6432122	Gilson et al.	Aug 2002	B1
6451036	Heitzmann et al.	Sep 2002	B1
6458103	Albert et al.	Oct 2002	B1
6475236	Roubin et al.	Nov 2002	B1
6485502	Don Michael	Nov 2002	B2
6508782	Evans et al.	Jan 2003	B1
6511492	Rosenbluth et al.	Jan 2003	B1
6514273	Voss et al.	Feb 2003	B1
6530923	Dubrul et al.	Mar 2003	B1
6530935	Wensel et al.	Mar 2003	B2
6540722	Boyle et al.	Apr 2003	B1
6544276	Azizi	Apr 2003	B1
6544278	Vrba et al.	Apr 2003	B1
6544279	Hopkins et al.	Apr 2003	B1
6551342	Shen et al.	Apr 2003	B1
6564828	Ishida	May 2003	B1
6569181	Burns	May 2003	B1
6575995	Huter et al.	Jun 2003	B1
6589263	Hopkins et al.	Jul 2003	B1
6589264	Barbut et al.	Jul 2003	B1
6596011	Johnson et al.	Jul 2003	B2
6602271	Adams et al.	Aug 2003	B2
6605074	Zadno-azizi et al.	Aug 2003	B2
6605102	Mazzocchi et al.	Aug 2003	B1
6610077	Hancock et al.	Aug 2003	B1
6620148	Tsugita	Sep 2003	B1
6620179	Brook et al.	Sep 2003	B2
6620182	Khosravi et al.	Sep 2003	B1
6623460	Heck	Sep 2003	B1
6635068	Dubrul et al.	Oct 2003	B1
6645222	Parodi et al.	Nov 2003	B1
6660013	Rabiner et al.	Dec 2003	B2
6660014	Demarais et al.	Dec 2003	B2
6663650	Sepetka et al.	Dec 2003	B2
6692504	Kurz et al.	Feb 2004	B2
6699260	Dubrul et al.	Mar 2004	B2
6702830	Demarais et al.	Mar 2004	B1
6719717	Johnson et al.	Apr 2004	B1
6755847	Eskuri	Jun 2004	B2
6767353	Shiber	Jul 2004	B1
6790204	Zadno-azizi et al.	Sep 2004	B2
6800080	Bates	Oct 2004	B1
6818006	Douk et al.	Nov 2004	B2
6824545	Sepetka et al.	Nov 2004	B2
6824550	Noriega et al.	Nov 2004	B1
6824553	Gene et al.	Nov 2004	B1
6830561	Jansen et al.	Dec 2004	B2
6846029	Ragner et al.	Jan 2005	B1
6902540	Dorros et al.	Jun 2005	B2
6908455	Hajianpour	Jun 2005	B2
6939361	Kleshinski	Sep 2005	B1
6942682	Vrba et al.	Sep 2005	B2
6945977	Demarais et al.	Sep 2005	B2
6960189	Bates et al.	Nov 2005	B2
6960222	Vo et al.	Nov 2005	B2
7004931	Hogendijk	Feb 2006	B2
7004954	Voss et al.	Feb 2006	B1
7036707	Aota et al.	May 2006	B2
7041084	Fotjik	May 2006	B2
7052500	Bashiri et al.	May 2006	B2
7056328	Arnott	Jun 2006	B2
7063707	Bose et al.	Jun 2006	B2
7069835	Nishri et al.	Jul 2006	B2
7094249	Thomas et al.	Aug 2006	B1
7122034	Belhe et al.	Oct 2006	B2
7128073	van der Burg et al.	Oct 2006	B1
7152605	Khairkhahan et al.	Dec 2006	B2
7179273	Palmer et al.	Feb 2007	B1
7223253	Hogendijk	May 2007	B2
7232432	Fulton, III et al.	Jun 2007	B2
7244243	Lary	Jul 2007	B2
7285126	Sepetka et al.	Oct 2007	B2
7300458	Henkes et al.	Nov 2007	B2
7306618	Demond et al.	Dec 2007	B2
7320698	Eskuri	Jan 2008	B2
7323002	Johnson et al.	Jan 2008	B2
7331980	Dubrul et al.	Feb 2008	B2
7481805	Magnusson	Jan 2009	B2
7534234	Fotjik	May 2009	B2
7578830	Kusleika et al.	Aug 2009	B2
7621870	Berrada et al.	Nov 2009	B2
7674247	Fotjik	Mar 2010	B2
7678131	Muller	Mar 2010	B2
7691121	Rosenbluth et al.	Apr 2010	B2
7695458	Belley et al.	Apr 2010	B2
7713282	Frazier et al.	May 2010	B2
7722641	van der Burg et al.	May 2010	B2
7763010	Evans et al.	Jul 2010	B2
7766934	Pal et al.	Aug 2010	B2
7775501	Kees	Aug 2010	B2
7780696	Daniel et al.	Aug 2010	B2
7815608	Schafersman et al.	Oct 2010	B2
7837630	Nieoson et al.	Nov 2010	B2
7905877	Jilnenez et al.	Mar 2011	B1
7905896	Straub	Mar 2011	B2
7938809	Lampropoulos et al.	May 2011	B2
7938820	Webster et al.	May 2011	B2
7967790	Whiting et al.	Jun 2011	B2
7976511	Fotjik	Jul 2011	B2
7993302	Hebert et al.	Aug 2011	B2
7993363	Demond et al.	Aug 2011	B2
8021351	Boldenow et al.	Sep 2011	B2
8043313	Krolik et al.	Oct 2011	B2
8052640	Fiorella et al.	Nov 2011	B2
8057496	Fischer, Jr.	Nov 2011	B2
8057497	Raju et al.	Nov 2011	B1
8066757	Ferrera et al.	Nov 2011	B2
8070694	Galdonik et al.	Dec 2011	B2
8070769	Broome	Dec 2011	B2
8070791	Ferrera et al.	Dec 2011	B2
8075510	Aklog et al.	Dec 2011	B2
8080032	van der Burg et al.	Dec 2011	B2
8088140	Ferrera et al.	Jan 2012	B2
8092486	Berrada et al.	Jan 2012	B2
8100935	Rosenbluth et al.	Jan 2012	B2
8109962	Pal	Feb 2012	B2
8118829	Carrison et al.	Feb 2012	B2
8197493	Ferrera et al.	Jun 2012	B2
8246641	Osborne et al.	Aug 2012	B2
8261648	Marchand et al.	Sep 2012	B1
8267897	Wells	Sep 2012	B2
8298257	Sepetka et al.	Oct 2012	B2
8317748	Fiorella et al.	Nov 2012	B2
8337450	Fotjik	Dec 2012	B2
RE43902	Hopkins et al.	Jan 2013	E
8343167	Henson	Jan 2013	B2
8357178	Grandfield et al.	Jan 2013	B2
8361104	Jones et al.	Jan 2013	B2
8409215	Sepetka et al.	Apr 2013	B2
8480708	Kassab et al.	Jul 2013	B2
8486105	Demond et al.	Jul 2013	B2
8491539	Fotjik	Jul 2013	B2
8512352	Martin	Aug 2013	B2
8523897	van der Burg et al.	Sep 2013	B2
8535283	Heaton	Sep 2013	B2
8535334	Martin	Sep 2013	B2
8535343	van der Burg et al.	Sep 2013	B2
8545526	Martin et al.	Oct 2013	B2
8568432	Straub	Oct 2013	B2
8568465	Freudenthal et al.	Oct 2013	B2
8574262	Ferrera et al.	Nov 2013	B2
8579915	French et al.	Nov 2013	B2
8585713	Ferrera et al.	Nov 2013	B2
8608754	Wensel et al.	Dec 2013	B2
8647367	Kassab et al.	Feb 2014	B2
8657867	Dorn et al.	Feb 2014	B2
8696622	Fiorella et al.	Apr 2014	B2
8715314	Janardhan et al.	May 2014	B1
8721714	Kelley	May 2014	B2
8753322	Hu	Jun 2014	B2
8771289	Mohiuddin et al.	Jul 2014	B2
8777893	Malewicz	Jul 2014	B2
8784441	Rosenbluth et al.	Jul 2014	B2
8784442	Jones et al.	Jul 2014	B2
8784469	Kassab	Jul 2014	B2
8795305	Martin et al.	Aug 2014	B2
8795345	Grandfield et al.	Aug 2014	B2
8801748	Martin	Aug 2014	B2
8808259	Walton et al.	Aug 2014	B2
8814927	Shin et al.	Aug 2014	B2
8820207	Marchand et al.	Sep 2014	B2
8826791	Thompson et al.	Sep 2014	B2
8828044	Aggerholm et al.	Sep 2014	B2
8833224	Thompson et al.	Sep 2014	B2
8834519	van der Burg et al.	Sep 2014	B2
8845621	Fotjik	Sep 2014	B2
8852205	Brady et al.	Oct 2014	B2
8852226	Gilson et al.	Oct 2014	B2
8939991	Krolik et al.	Jan 2015	B2
8945143	Ferrera et al.	Feb 2015	B2
8945172	Ferrera et al.	Feb 2015	B2
8956384	Berrada et al.	Feb 2015	B2
8992504	Castella et al.	Mar 2015	B2
9005172	Chung	Apr 2015	B2
9011551	Oral et al.	Apr 2015	B2
9028401	Bacich et al.	May 2015	B1
9078682	Lenker et al.	Jul 2015	B2
9101382	Krolik et al.	Aug 2015	B2
9125683	Farhangnia et al.	Sep 2015	B2
9126016	Fulton	Sep 2015	B2
9149609	Ansel et al.	Oct 2015	B2
9155552	Ulm, III	Oct 2015	B2
9161766	Slee et al.	Oct 2015	B2
9168043	van der Burg et al.	Oct 2015	B2
9173668	Ulm, III	Nov 2015	B2
9186487	Dubrul et al.	Nov 2015	B2
9204887	Cully et al.	Dec 2015	B2
9216277	Myers	Dec 2015	B2
9241669	Pugh et al.	Jan 2016	B2
9358037	Farhangnia et al.	Jan 2016	B2
9259237	Quick et al.	Feb 2016	B2
9265512	Carrison et al.	Feb 2016	B2
9283066	Hopkins et al.	Mar 2016	B2
9301769	Brady et al.	Apr 2016	B2
9351747	Kugler et al.	May 2016	B2
9439664	Sos	Sep 2016	B2
9439751	White et al.	Sep 2016	B2
9456834	Folk	Oct 2016	B2
9463035	Greenhalgh et al.	Oct 2016	B1
9463036	Brady et al.	Oct 2016	B2
9526864	Quick	Dec 2016	B2
9526865	Quick	Dec 2016	B2
9532792	Galdonik et al.	Jan 2017	B2
9566073	Kassab et al.	Feb 2017	B2
9566424	Pessin	Feb 2017	B2
9579116	Nguyen et al.	Feb 2017	B1
9581942	Shippert	Feb 2017	B1
9616213	Furnish et al.	Apr 2017	B2
9636206	Nguyen et al.	May 2017	B2
9643035	Mastenbroek	May 2017	B2
9662129	Galdonik et al.	May 2017	B2
9700332	Marchand et al.	Jul 2017	B2
9717488	Kassab et al.	Aug 2017	B2
9717514	Martin et al.	Aug 2017	B2
9717519	Rosenbluth et al.	Aug 2017	B2
9744024	Nguyen et al.	Aug 2017	B2
9757137	Krolik et al.	Sep 2017	B2
9827084	Bonnette et al.	Nov 2017	B2
9844386	Nguyen et al.	Dec 2017	B2
9844387	Marchand et al.	Dec 2017	B2
9848975	Hauser	Dec 2017	B2
9849014	Kusleika	Dec 2017	B2
9884387	Plha	Feb 2018	B2
9962178	Greenhalgh et al.	May 2018	B2
9980813	Eller	May 2018	B2
9999493	Nguyen et al.	Jun 2018	B2
10004531	Rosenbluth et al.	Jun 2018	B2
10010335	Greenhalgh et al.	Jul 2018	B2
10016266	Hauser	Jul 2018	B2
10028759	Wallace et al.	Jul 2018	B2
10045790	Cox et al.	Aug 2018	B2
10058339	Galdonik et al.	Aug 2018	B2
10098651	Marchand et al.	Oct 2018	B2
10130385	Farhangnia et al.	Nov 2018	B2
10183159	Nobles et al.	Jan 2019	B2
10226263	Look et al.	Mar 2019	B2
10238406	Cox et al.	Mar 2019	B2
10271864	Greenhalgh et al.	Apr 2019	B2
10327883	Yachia	Jun 2019	B2
10335186	Rosenbluth et al.	Jul 2019	B2
10342571	Marchand et al.	Jul 2019	B2
10349960	Quick	Jul 2019	B2
10383644	Molaei et al.	Aug 2019	B2
10384034	Carrison et al.	Aug 2019	B2
10456555	Carrison et al.	Oct 2019	B2
10478535	Ogle	Nov 2019	B2
10485952	Carrison et al.	Nov 2019	B2
10524811	Marchand et al.	Jan 2020	B2
10531883	Deville	Jan 2020	B1
10588655	Rosenbluth et al.	Mar 2020	B2
10648268	Jaffrey et al.	May 2020	B2
10695159	Hauser	Jun 2020	B2
10709471	Rosenbluth et al.	Jul 2020	B2
10772636	Kassab et al.	Sep 2020	B2
10799331	Hauser	Oct 2020	B2
10912577	Marchand et al.	Feb 2021	B2
10926060	Stern et al.	Feb 2021	B2
10953195	Jalgaonkar et al.	Mar 2021	B2
10960114	Goisis	Mar 2021	B2
11000682	Merritt et al.	May 2021	B2
11013523	Arad Hadar	May 2021	B2
11058445	Cox et al.	Jul 2021	B2
11058451	Marchand et al.	Jul 2021	B2
11065019	Chou et al.	Jul 2021	B1
11147571	Cox et al.	Oct 2021	B2
11154314	Quick	Oct 2021	B2
11166703	Kassab et al.	Nov 2021	B2
11185664	Carrison et al.	Nov 2021	B2
11213356	Tanner et al.	Jan 2022	B2
11224450	Chou et al.	Jan 2022	B2
11224721	Carrison et al.	Jan 2022	B2
11259821	Buck et al.	Mar 2022	B2
11305094	Carrison et al.	Apr 2022	B2
11383064	Carrison et al.	Jul 2022	B2
11395903	Carrison et al.	Jul 2022	B2
11406801	Fojtik et al.	Aug 2022	B2
11433218	Quick et al.	Sep 2022	B2
11439799	Buck et al.	Sep 2022	B2
11457936	Buck et al.	Oct 2022	B2
11529158	Hauser	Dec 2022	B2
11554005	Merritt et al.	Jan 2023	B2
11559382	Merritt et al.	Jan 2023	B2
11576691	Chou et al.	Feb 2023	B2
11596768	Stern et al.	Mar 2023	B2
11642209	Merritt et al.	May 2023	B2
11648028	Rosenbluth et al.	May 2023	B2
11697011	Merritt et al.	Jul 2023	B2
11697012	Merritt et al.	Jul 2023	B2
11744691	Merritt et al.	Sep 2023	B2
11806033	Marchand et al.	Nov 2023	B2
11832837	Hauser	Dec 2023	B2
11832838	Hauser	Dec 2023	B2
11833023	Merritt et al.	Dec 2023	B2
11839393	Hauser	Dec 2023	B2
11844921	Merritt et al.	Dec 2023	B2
11849963	Quick	Dec 2023	B2
11865291	Merritt et al.	Jan 2024	B2
11890180	Merritt et al.	Feb 2024	B2
11918243	Marchand et al.	Mar 2024	B2
11918244	Marchand et al.	Mar 2024	B2
11925369	Hauser	Mar 2024	B2
11937834	Dinh	Mar 2024	B2
11937838	Cox et al.	Mar 2024	B2
20010004699	Gittings et al.	Jun 2001	A1
20010031981	Evans et al.	Oct 2001	A1
20010041881	Sarge et al.	Nov 2001	A1
20010041909	Tsugita et al.	Nov 2001	A1
20010049486	Evans et al.	Dec 2001	A1
20010051810	Dubrul et al.	Dec 2001	A1
20020022858	Demond et al.	Feb 2002	A1
20020022859	Hogendijk	Feb 2002	A1
20020026211	Khosravi et al.	Feb 2002	A1
20020032455	Boock et al.	Mar 2002	A1
20020049452	Kurz et al.	Apr 2002	A1
20020095161	Dhindsa	Jul 2002	A1
20020095171	Belef	Jul 2002	A1
20020111648	Kusleika et al.	Aug 2002	A1
20020120277	Hauschild et al.	Aug 2002	A1
20020147458	Hiblar et al.	Oct 2002	A1
20020151918	Lafontaine et al.	Oct 2002	A1
20020156457	Fisher	Oct 2002	A1
20020161392	Dubrul	Oct 2002	A1
20020169474	Kusleika	Nov 2002	A1
20020173819	Leeflang et al.	Nov 2002	A1
20020188276	Evans et al.	Dec 2002	A1
20030023263	Krolik et al.	Jan 2003	A1
20030083693	Daniel et al.	May 2003	A1
20030100919	Hopkins et al.	May 2003	A1
20030114875	Sjostrom	Jun 2003	A1
20030116731	Hartley	Jun 2003	A1
20030125663	Coleman et al.	Jul 2003	A1
20030135151	Deng	Jul 2003	A1
20030135230	Massey et al.	Jul 2003	A1
20030135258	Andreas et al.	Jul 2003	A1
20030153873	Luther et al.	Aug 2003	A1
20030153973	Soun et al.	Aug 2003	A1
20030168068	Poole et al.	Sep 2003	A1
20030176884	Berrada et al.	Sep 2003	A1
20030191516	Weldon et al.	Oct 2003	A1
20030208224	Broome	Nov 2003	A1
20030216774	Larson	Nov 2003	A1
20030225379	Schaffer et al.	Dec 2003	A1
20040019310	Hogendijk	Jan 2004	A1
20040039351	Barrett	Feb 2004	A1
20040039412	Isshiki et al.	Feb 2004	A1
20040068288	Palmer et al.	Apr 2004	A1
20040073243	Sepetka et al.	Apr 2004	A1
20040098033	Leeflang et al.	May 2004	A1
20040102807	Kusleika et al.	May 2004	A1
20040122359	Wenz	Jun 2004	A1
20040127936	Salahieh et al.	Jul 2004	A1
20040133232	Rosenbluth et al.	Jul 2004	A1
20040138525	Saadat et al.	Jul 2004	A1
20040138692	Phung et al.	Jul 2004	A1
20040167567	Cano et al.	Aug 2004	A1
20040199201	Kellett et al.	Oct 2004	A1
20040199202	Dubrul et al.	Oct 2004	A1
20040260344	Lyons et al.	Dec 2004	A1
20040267272	Henniges et al.	Dec 2004	A1
20050004534	Lockwood et al.	Jan 2005	A1
20050033172	Dubrul et al.	Feb 2005	A1
20050038468	Panetta et al.	Feb 2005	A1
20050054995	Barzell et al.	Mar 2005	A1
20050055047	Greenhalgh	Mar 2005	A1
20050085769	MacMahon et al.	Apr 2005	A1
20050085826	Nair et al.	Apr 2005	A1
20050085846	Carrison et al.	Apr 2005	A1
20050085849	Sepetka et al.	Apr 2005	A1
20050119668	Teague et al.	Jun 2005	A1
20050131387	Pursley	Jun 2005	A1
20050177132	Lentz et al.	Aug 2005	A1
20050187570	Nguyen et al.	Aug 2005	A1
20050203605	Dolan	Sep 2005	A1
20050283165	Gadberry	Dec 2005	A1
20050283166	Greenhalgh et al.	Dec 2005	A1
20050283186	Berrada et al.	Dec 2005	A1
20060020286	Niermann	Jan 2006	A1
20060042786	West	Mar 2006	A1
20060047286	West	Mar 2006	A1
20060074401	Ross	Apr 2006	A1
20060089533	Ziegler et al.	Apr 2006	A1
20060100662	Daniel et al.	May 2006	A1
20060155305	Freudenthal et al.	Jul 2006	A1
20060173525	Behl et al.	Aug 2006	A1
20060195137	Sepetka et al.	Aug 2006	A1
20060200221	Malewicz	Sep 2006	A1
20060217664	Hattler et al.	Sep 2006	A1
20060224177	Finitsis	Oct 2006	A1
20060229645	Bonnette et al.	Oct 2006	A1
20060247500	Voegele et al.	Nov 2006	A1
20060253145	Lucas	Nov 2006	A1
20060264905	Eskridge et al.	Nov 2006	A1
20060276874	Wilson et al.	Dec 2006	A1
20060282111	Morsi	Dec 2006	A1
20060293696	Fahey et al.	Dec 2006	A1
20070010787	Hackett et al.	Jan 2007	A1
20070038225	Osborne	Feb 2007	A1
20070093744	Elmaleh	Apr 2007	A1
20070112374	Paul et al.	May 2007	A1
20070118165	DeMello et al.	May 2007	A1
20070149996	Coughlin	Jun 2007	A1
20070161963	Smalling	Jul 2007	A1
20070179513	Deutsch	Aug 2007	A1
20070191866	Palmer et al.	Aug 2007	A1
20070198028	Miloslavski et al.	Aug 2007	A1
20070208361	Okushi et al.	Sep 2007	A1
20070208367	Fiorella et al.	Sep 2007	A1
20070213753	Waller	Sep 2007	A1
20070213765	Adams et al.	Sep 2007	A1
20070233043	Dayton et al.	Oct 2007	A1
20070255252	Mehta	Nov 2007	A1
20070288054	Tanaka et al.	Dec 2007	A1
20080015541	Rosenbluth et al.	Jan 2008	A1
20080087853	Kees	Apr 2008	A1
20080088055	Ross	Apr 2008	A1
20080157017	Macatangay et al.	Jul 2008	A1
20080167678	Morsi	Jul 2008	A1
20080183136	Lenker et al.	Jul 2008	A1
20080228209	DeMello et al.	Sep 2008	A1
20080234715	Pesce et al.	Sep 2008	A1
20080234722	Bonnette et al.	Sep 2008	A1
20080262528	Martin	Oct 2008	A1
20080269798	Ramzipoor et al.	Oct 2008	A1
20080294096	Uber, III et al.	Nov 2008	A1
20080300466	Gresham	Dec 2008	A1
20080312681	Ansel et al.	Dec 2008	A1
20090018566	Escudero et al.	Jan 2009	A1
20090054918	Henson	Feb 2009	A1
20090062841	Amplatz et al.	Mar 2009	A1
20090069828	Martin et al.	Mar 2009	A1
20090076417	Jones	Mar 2009	A1
20090160112	Ostrovsky	Jun 2009	A1
20090163846	Aklog et al.	Jun 2009	A1
20090182362	Thompson et al.	Jul 2009	A1
20090192495	Ostrovsky et al.	Jul 2009	A1
20090281525	Harding et al.	Nov 2009	A1
20090292307	Razack	Nov 2009	A1
20090299393	Martin et al.	Dec 2009	A1
20090312786	Trask et al.	Dec 2009	A1
20100016837	Howat	Jan 2010	A1
20100030256	Dubrul et al.	Feb 2010	A1
20100042136	Berrada et al.	Feb 2010	A1
20100087844	Fischer, Jr.	Apr 2010	A1
20100087850	Razack	Apr 2010	A1
20100094201	Mallaby	Apr 2010	A1
20100106081	Brandeis	Apr 2010	A1
20100114017	Lenker et al.	May 2010	A1
20100114113	Dubrul et al.	May 2010	A1
20100121312	Gielenz et al.	May 2010	A1
20100137846	Desai et al.	Jun 2010	A1
20100190156	Van Wordragen et al.	Jul 2010	A1
20100204712	Mallaby	Aug 2010	A1
20100217276	Garrison et al.	Aug 2010	A1
20100249815	Jantzen et al.	Sep 2010	A1
20100268264	Bonnette et al.	Oct 2010	A1
20100318178	Rapaport et al.	Dec 2010	A1
20110034986	Chou et al.	Feb 2011	A1
20110034987	Kennedy	Feb 2011	A1
20110054405	Whiting et al.	Mar 2011	A1
20110060212	Slee et al.	Mar 2011	A1
20110071503	Takagi et al.	Mar 2011	A1
20110118817	Gunderson et al.	May 2011	A1
20110125181	Brady et al.	May 2011	A1
20110144592	Wong et al.	Jun 2011	A1
20110152823	Mohiuddin et al.	Jun 2011	A1
20110152889	Ashland	Jun 2011	A1
20110152993	Marchand et al.	Jun 2011	A1
20110160742	Ferrera et al.	Jun 2011	A1
20110160763	Ferrera et al.	Jun 2011	A1
20110190806	Wittens	Aug 2011	A1
20110196309	Wells	Aug 2011	A1
20110196414	Porter et al.	Aug 2011	A1
20110213290	Chin et al.	Sep 2011	A1
20110213403	Aboytes	Sep 2011	A1
20110224707	Miloslavski et al.	Sep 2011	A1
20110245807	Sakata et al.	Oct 2011	A1
20110251629	Galdonik et al.	Oct 2011	A1
20110264132	Strauss et al.	Oct 2011	A1
20110264133	Hanlon et al.	Oct 2011	A1
20110265681	Allen et al.	Nov 2011	A1
20110288529	Fulton	Nov 2011	A1
20110288572	Martin	Nov 2011	A1
20110309037	Lee	Dec 2011	A1
20110319917	Ferrera et al.	Dec 2011	A1
20120059309	di Palma et al.	Mar 2012	A1
20120059356	di Palma et al.	Mar 2012	A1
20120083824	Berrada et al.	Apr 2012	A1
20120083868	Shrivastava	Apr 2012	A1
20120089216	Rapaport et al.	Apr 2012	A1
20120095448	Kajii	Apr 2012	A1
20120101480	Ingle et al.	Apr 2012	A1
20120101510	Lenker et al.	Apr 2012	A1
20120109109	Kajii	May 2012	A1
20120138832	Townsend	Jun 2012	A1
20120143239	Aklog et al.	Jun 2012	A1
20120165919	Cox et al.	Jun 2012	A1
20120172918	Fifer et al.	Jul 2012	A1
20120179181	Straub et al.	Jul 2012	A1
20120197277	Stinis	Aug 2012	A1
20120232655	Lorrison et al.	Sep 2012	A1
20120271105	Nakamura et al.	Oct 2012	A1
20120271231	Agrawal	Oct 2012	A1
20120277788	Cattaneo	Nov 2012	A1
20120310166	Huff	Dec 2012	A1
20130030460	Marks et al.	Jan 2013	A1
20130035628	Garrison et al.	Feb 2013	A1
20130046332	Jones et al.	Feb 2013	A1
20130066348	Fiorella et al.	Mar 2013	A1
20130092012	Marchand et al.	Apr 2013	A1
20130096571	Massicotte et al.	Apr 2013	A1
20130102996	Strauss	Apr 2013	A1
20130116708	Ziniti et al.	May 2013	A1
20130116721	Takagi et al.	May 2013	A1
20130123705	Holm et al.	May 2013	A1
20130126559	Cowan et al.	May 2013	A1
20130144326	Brady et al.	Jun 2013	A1
20130150793	Beissel et al.	Jun 2013	A1
20130165871	Fiorella et al.	Jun 2013	A1
20130184703	Shireman et al.	Jul 2013	A1
20130190701	Kirn	Jul 2013	A1
20130197454	Shibata et al.	Aug 2013	A1
20130197567	Brady et al.	Aug 2013	A1
20130204297	Melsheimer et al.	Aug 2013	A1
20130226196	Smith	Aug 2013	A1
20130270161	Kumar et al.	Oct 2013	A1
20130281788	Garrison	Oct 2013	A1
20130289608	Tanaka et al.	Oct 2013	A1
20130317589	Martin et al.	Nov 2013	A1
20130345739	Brady et al.	Dec 2013	A1
20140005712	Martin	Jan 2014	A1
20140005713	Bowman	Jan 2014	A1
20140005715	Castella et al.	Jan 2014	A1
20140005717	Martin et al.	Jan 2014	A1
20140025048	Ward	Jan 2014	A1
20140031856	Martin	Jan 2014	A1
20140046133	Nakamura et al.	Feb 2014	A1
20140046243	Ray et al.	Feb 2014	A1
20140052161	Cully et al.	Feb 2014	A1
20140074144	Shrivastava et al.	Mar 2014	A1
20140121672	Folk	May 2014	A1
20140155830	Bonnette	Jun 2014	A1
20140155980	Turjman	Jun 2014	A1
20140163615	Gadlage et al.	Jun 2014	A1
20140180055	Glynn et al.	Jun 2014	A1
20140180397	Gerberding et al.	Jun 2014	A1
20140155908	Rosenbluth et al.	Jul 2014	A1
20140188127	Dubrul et al.	Jul 2014	A1
20140188143	Martin et al.	Jul 2014	A1
20140222070	Belson et al.	Aug 2014	A1
20140236219	Dubrul et al.	Aug 2014	A1
20140243882	Ma	Aug 2014	A1
20140257253	Jemison	Sep 2014	A1
20140257363	Lippert	Sep 2014	A1
20140276403	Follmer et al.	Sep 2014	A1
20140296868	Garrison et al.	Oct 2014	A1
20140303658	Bonnette et al.	Oct 2014	A1
20140318354	Thompson et al.	Oct 2014	A1
20140324091	Rosenbluth et al.	Oct 2014	A1
20140330286	Wallace et al.	Nov 2014	A1
20140336691	Jones et al.	Nov 2014	A1
20140343593	Chin et al.	Nov 2014	A1
20140364896	Consigny	Dec 2014	A1
20140371779	Vale et al.	Dec 2014	A1
20150005781	Lund-Clausen et al.	Jan 2015	A1
20150005792	Ahn	Jan 2015	A1
20150018859	Quick et al.	Jan 2015	A1
20150018860	Quick	Jan 2015	A1
20150018929	Martin et al.	Jan 2015	A1
20150025555	Sos	Jan 2015	A1
20150032144	Holloway	Jan 2015	A1
20150059908	Mollen	Mar 2015	A1
20150088190	Jensen	Mar 2015	A1
20150127035	Trapp et al.	May 2015	A1
20150133990	Davidson	May 2015	A1
20150150672	Ma	Jun 2015	A1
20150164523	Brady et al.	Jun 2015	A1
20150164666	Johnson et al.	Jun 2015	A1
20150173782	Garrison et al.	Jun 2015	A1
20150190155	Ulm, III	Jul 2015	A1
20150190156	Ulm, III	Jul 2015	A1
20150196380	Berrada et al.	Jul 2015	A1
20150196744	Aboytes	Jul 2015	A1
20150209058	Ferrera et al.	Jul 2015	A1
20150209165	Grandfield et al.	Jul 2015	A1
20150238207	Cox et al.	Aug 2015	A1
20150250578	Cook et al.	Sep 2015	A1
20150265299	Cooper et al.	Sep 2015	A1
20150305756	Rosenbluth	Oct 2015	A1
20150305859	Eller	Oct 2015	A1
20150352325	Quick	Dec 2015	A1
20150360001	Quick	Dec 2015	A1
20150374391	Quick	Dec 2015	A1
20160022293	Dubrul et al.	Jan 2016	A1
20160030708	Casiello et al.	Feb 2016	A1
20160038267	Allen et al.	Feb 2016	A1
20160058540	Don Michael	Mar 2016	A1
20160074627	Cottone	Mar 2016	A1
20160106353	Schuetz	Apr 2016	A1
20160106448	Brady et al.	Apr 2016	A1
20160106449	Brady et al.	Apr 2016	A1
20160113663	Brady et al.	Apr 2016	A1
20160113664	Brady et al.	Apr 2016	A1
20160113665	Brady et al.	Apr 2016	A1
20160113666	Quick	Apr 2016	A1
20160135829	Holochwost et al.	May 2016	A1
20160143721	Rosenbluth	May 2016	A1
20160151605	Welch et al.	Jun 2016	A1
20160192912	Kassab et al.	Jul 2016	A1
20160206344	Bruzzi et al.	Jul 2016	A1
20160008014	Rosenbluth	Aug 2016	A1
20160220741	Garrison et al.	Aug 2016	A1
20160220795	Korkuch et al.	Aug 2016	A1
20160228134	Martin et al.	Aug 2016	A1
20160262774	Honda	Sep 2016	A1
20160262790	Rosenbluth et al.	Sep 2016	A1
20160287276	Cox et al.	Oct 2016	A1
20160367285	Sos	Dec 2016	A1
20170014560	Minskoff et al.	Jan 2017	A1
20170021130	Dye	Jan 2017	A1
20170037548	Lee	Feb 2017	A1
20170042571	Levi	Feb 2017	A1
20170049942	Conlan et al.	Feb 2017	A1
20170056032	Look	Mar 2017	A1
20170058623	Jaffrey et al.	Mar 2017	A1
20170079672	Quick	Mar 2017	A1
20170086864	Greenhalgh et al.	Mar 2017	A1
20170100142	Look et al.	Apr 2017	A1
20170105743	Vale et al.	Apr 2017	A1
20170105745	Rosenbluth et al.	Apr 2017	A1
20170112514	Marchand et al.	Apr 2017	A1
20170113005	Linder et al.	Apr 2017	A1
20170143359	Nguyen et al.	May 2017	A1
20170143880	Luxon et al.	May 2017	A1
20170143938	Ogle et al.	May 2017	A1
20170172591	Ulm, III	Jun 2017	A1
20170112513	Marchand et al.	Jul 2017	A1
20170189041	Cox et al.	Jul 2017	A1
20170196576	Long et al.	Jul 2017	A1
20170233908	Kroczynski et al.	Aug 2017	A1
20170252057	Bonnette et al.	Sep 2017	A1
20170265878	Marchand et al.	Sep 2017	A1
20170281204	Garrison et al.	Oct 2017	A1
20170303939	Greenhalgh et al.	Oct 2017	A1
20170303942	Greenhalgh et al.	Oct 2017	A1
20170303947	Greenhalgh et al.	Oct 2017	A1
20170303948	Wallace et al.	Oct 2017	A1
20170319221	Chu	Nov 2017	A1
20170325839	Rosenbluth et al.	Nov 2017	A1
20170340867	Accisano, II	Nov 2017	A1
20170348014	Wallace et al.	Dec 2017	A1
20180014840	Panian	Jan 2018	A1
20180042623	Batiste	Feb 2018	A1
20180042624	Greenhalgh et al.	Feb 2018	A1
20180042626	Greenhalgh et al.	Feb 2018	A1
20180055999	Bare	Mar 2018	A1
20180064453	Garrison et al.	Mar 2018	A1
20180064454	Losordo et al.	Mar 2018	A1
20180070968	Wallace et al.	Mar 2018	A1
20180092652	Marchand et al.	Apr 2018	A1
20180104404	Ngo-Chu	Apr 2018	A1
20180105963	Quick	Apr 2018	A1
20180125512	Nguyen et al.	May 2018	A1
20180184912	Al-Ali	Jul 2018	A1
20180193043	Marchand et al.	Jul 2018	A1
20180236205	Krautkremer et al.	Aug 2018	A1
20180250498	Stern et al.	Sep 2018	A1
20180256177	Cooper et al.	Sep 2018	A1
20180256178	Cox et al.	Sep 2018	A1
20180296240	Rosenbluth et al.	Oct 2018	A1
20180344339	Cox et al.	Dec 2018	A1
20180361116	Quick et al.	Dec 2018	A1
20190000492	Casey et al.	Jan 2019	A1
20190015298	Beatty	Jan 2019	A1
20190046219	Marchand et al.	Feb 2019	A1
20190070401	Merritt et al.	Mar 2019	A1
20190117244	Wallace et al.	Apr 2019	A1
20190133622	Wallace et al.	May 2019	A1
20190133623	Wallace et al.	May 2019	A1
20190133624	Wallace et al.	May 2019	A1
20190133625	Wallace et al.	May 2019	A1
20190133626	Wallace et al.	May 2019	A1
20190133627	Wallace et al.	May 2019	A1
20190150959	Cox et al.	May 2019	A1
20190223893	Gilvarry et al.	Jul 2019	A1
20190231373	Quick	Aug 2019	A1
20190239910	Brady et al.	Aug 2019	A1
20190321071	Marchand et al.	Oct 2019	A1
20190328411	Vale et al.	Oct 2019	A1
20190336142	Torrie et al.	Nov 2019	A1
20190336148	Greenhalgh et al.	Nov 2019	A1
20190365395	Tran et al.	Dec 2019	A1
20190366036	Jalgaonkar et al.	Dec 2019	A1
20200022711	Look et al.	Jan 2020	A1
20200046368	Merritt et al.	Feb 2020	A1
20200046940	Carrison et al.	Feb 2020	A1
20200054861	Korkuch et al.	Feb 2020	A1
20200113412	Jensen	Apr 2020	A1
20200121334	Galdonik et al.	Apr 2020	A1
20200129741	Kawwas et al.	Apr 2020	A1
20210022843	Hauser	Jan 2021	A1
20210038385	Popp et al.	Feb 2021	A1
20210113224	Dinh	Apr 2021	A1
20210128182	Teigen et al.	May 2021	A1
20210137667	Sonnette et al.	May 2021	A1
20210138194	Carrison et al.	May 2021	A1
20210186541	Thress	Jun 2021	A1
20210205577	Jalgaonkar et al.	Jul 2021	A1
20210236148	Marchand et al.	Aug 2021	A1
20210290925	Merritt et al.	Sep 2021	A1
20210315598	Buck et al.	Oct 2021	A1
20210316127	Buck et al.	Oct 2021	A1
20210330344	Rosenbluth et al.	Oct 2021	A1
20210378694	Thress et al.	Dec 2021	A1
20210393278	O'Malley et al.	Dec 2021	A1
20210404464	Patoskie	Dec 2021	A1
20220000505	Hauser	Jan 2022	A1
20220000506	Hauser	Jan 2022	A1
20220000507	Hauser	Jan 2022	A1
20220015798	Marchand et al.	Jan 2022	A1
20220022898	Cox et al.	Jan 2022	A1
20220033888	Schnall-Levin et al.	Feb 2022	A1
20220039815	Thress et al.	Feb 2022	A1
20220125451	Hauser	Apr 2022	A1
20220142638	Enright et al.	May 2022	A1
20220151647	Dolendo et al.	May 2022	A1
20220152355	Dolendo et al.	May 2022	A1
20220160381	Hauser	May 2022	A1
20220160382	Hauser	May 2022	A1
20220160383	Hauser	May 2022	A1
20220211400	Cox et al.	Jul 2022	A1
20220211992	Merritt et al.	Jul 2022	A1
20220240959	Quick	Aug 2022	A1
20220346800	Merritt et al.	Nov 2022	A1
20220346813	Quick	Nov 2022	A1
20220346814	Quick	Nov 2022	A1
20220347455	Merritt et al.	Nov 2022	A1
20220362512	Quick et al.	Nov 2022	A1
20220370761	Chou et al.	Nov 2022	A1
20230046775	Quick	Feb 2023	A1
20230059721	Chou et al.	Feb 2023	A1
20230062809	Merritt	Mar 2023	A1
20230070120	Cox et al.	Mar 2023	A1
20230122587	Chou et al.	Apr 2023	A1
20230200970	Merritt et al.	Jun 2023	A1
20230218310	Scheinblum et al.	Jul 2023	A1
20230218313	Rosenbluth et al.	Jul 2023	A1
20230218383	Merritt et al.	Jul 2023	A1
20230233311	Merritt et al.	Jul 2023	A1
20230240705	Rosenbluth et al.	Aug 2023	A1
20230240706	Rosenbluth et al.	Aug 2023	A1
20230241302	Merritt et al.	Aug 2023	A1
20230248380	Long et al.	Aug 2023	A1
20230270991	Merritt et al.	Aug 2023	A1
20230310138	Merritt et al.	Oct 2023	A1
20230310751	Merritt et al.	Oct 2023	A1
20230320834	Merritt et al.	Oct 2023	A1
20230329734	Marchand et al.	Oct 2023	A1
20230338130	Merritt et al.	Oct 2023	A1
20230338131	Merritt et al.	Oct 2023	A1
20230355256	Dinh	Nov 2023	A1
20230355259	Marchand et al.	Nov 2023	A1
20230355938	Merritt et al.	Nov 2023	A1
20230363776	Quick	Nov 2023	A1
20230363883	Merritt et al.	Nov 2023	A1
20230389932	Ozenne et al.	Dec 2023	A1
20230390045	Merritt et al.	Dec 2023	A1
20240058113	Strauss et al.	Feb 2024	A1
20240074771	Quick et al.	Mar 2024	A1
20240082540	Brodt et al.	Mar 2024	A1

Foreign Referenced Citations (109)

Number	Date	Country
2015210338	Aug 2015	AU
102186427	Sep 2011	CN
103764049	Apr 2014	CN
103932756	Jul 2014	CN
104068910	Oct 2014	CN
106178227	Dec 2016	CN
108348319	Jul 2018	CN
110652645	Jan 2020	CN
111281482	Jun 2020	CN
102017004383	Jul 2018	DE
1254634	Nov 2002	EP
1867290	Feb 2013	EP
2942624	Nov 2015	EP
3583972	Dec 2019	EP
3589348	Jan 2020	EP
3620204	Mar 2020	EP
3013404	Apr 2020	EP
4137070	Feb 2023	EP
1588072	Apr 1981	GB
2498349	Jul 2013	GB
H6190049	Jul 1994	JP
H07323090	Dec 1995	JP
2001522631	May 1999	JP
2004097807	Apr 2004	JP
2005-095242	Jun 2005	JP
2005230132	Sep 2005	JP
2005323702	Nov 2005	JP
2006094876	Apr 2006	JP
2007-222658	Sep 2007	JP
2011526820	Jan 2010	JP
WO1997017889	May 1997	WO
WO9833443	Aug 1998	WO
WO9838920	Sep 1998	WO
WO9839053	Sep 1998	WO
WO9851237	Nov 1998	WO
WO1999044542	Sep 1999	WO
WO0032118	Jun 2000	WO
WO2000053120	Sep 2000	WO
WO0202162	Jan 2002	WO
WO03015840	Feb 2003	WO
WO2004018916	Mar 2004	WO
WO2004093696	Nov 2004	WO
WO2005046736	May 2005	WO
WO2006029270	Mar 2006	WO
WO2006110186	Oct 2006	WO
WO2006124307	Nov 2006	WO
WO2007092820	Aug 2007	WO
WO2009082513	Jul 2009	WO
WO2009086482	Jul 2009	WO
WO2009155571	Dec 2009	WO
WO2010002549	Jan 2010	WO
WO2010010545	Jan 2010	WO
WO2010023671	Mar 2010	WO
WO2010049121	May 2010	WO
WO2010102307	Sep 2010	WO
WO2011032712	Mar 2011	WO
WO2011054531	May 2011	WO
WO2011073176	Jun 2011	WO
WO2012009675	Jan 2012	WO
WO2012011097	Jan 2012	WO
WO2012049652	Apr 2012	WO
WO2012065748	May 2012	WO
WO2012114633	Aug 2012	WO
WO2012120490	Sep 2012	WO
WO2012162437	Nov 2012	WO
WO2014047650	Mar 2014	WO
WO2014081892	May 2014	WO
WO2015006782	Jan 2015	WO
WO2015061365	Apr 2015	WO
WO2015121424	Aug 2015	WO
WO2015179329	Nov 2015	WO
WO2015189354	Dec 2015	WO
WO2015191646	Dec 2015	WO
WO2016014955	Jan 2016	WO
WO-2016014955	Jan 2016	WO
WO2017024258	Feb 2017	WO
WO2017058280	Apr 2017	WO
WO2017070702	Apr 2017	WO
WO2017106877	Jun 2017	WO
WO2017189535	Nov 2017	WO
WO2017189550	Nov 2017	WO
WO2017189591	Nov 2017	WO
WO2017189615	Nov 2017	WO
WO2017210487	Dec 2017	WO
WO2018049317	Mar 2018	WO
WO-2018065092	Apr 2018	WO
WO2018080590	May 2018	WO
WO2018148174	Aug 2018	WO
WO2019010318	Jan 2019	WO
WO2019050765	Mar 2019	WO
WO2019075444	Apr 2019	WO
WO2019094456	May 2019	WO
WO2019173475	Sep 2019	WO
WO2019222117	Nov 2019	WO
WO2019246240	Dec 2019	WO
WO2020036809	Feb 2020	WO
WO2021067134	Apr 2021	WO
WO2021076954	Apr 2021	WO
WO2021127202	Jun 2021	WO
WO2021248042	Dec 2021	WO
WO2022032173	Feb 2022	WO
WO2022103848	May 2022	WO
WO2022109021	May 2022	WO
WO2022109034	May 2022	WO
WO2023137341	Jul 2023	WO
WO2023147353	Aug 2023	WO
WO2023154612	Aug 2023	WO
WO2023192925	Oct 2023	WO
WO2023215779	Nov 2023	WO

Non-Patent Literature Citations (68)

Entry
English translation of Japanese Office Action dated Jun. 7, 2023 for Japanese Application No. 2021-507564, 7 pages.
Gibbs, et al., “Temporary Stent as a bail-out device during percutaneous transluminal coronary angioplasty: preliminary clinical experience,” British Heart Journal, 1994, 71:372-377, Oct. 12, 1993, 6 pgs.
Gupta, S. et al., “Acute Pulmonary Embolism Advances in Treatment”, JAPI, Association of Physicians India, Mar. 2008, vol. 56, 185-191.
International Search Report and Written Opinion for International App. No. PCT/US13/61470, dated Jan. 17, 2014, 7 pages.
International Search Report and Written Opinion for International App. No. PCT/US2014/046567, dated Nov. 3, 2014, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US2014/061645, dated Jan. 23, 2015, 15 pages.
International Search Report for International App. No. PCT/US13/71101, dated Mar. 31, 2014, 4 pages.
Konstantinides, S. et al., “Pulmonary embolism hotline 2012—Recent and expected trials”, Thrombosis and Haemostasis, Jan. 9, 2013:33; 43-50.
Konstantinides, S. et al., “Pulmonary embolism: risk assessment and management”, European Society of Cardiology; European Heart Journal, Sep. 7, 2012:33, 3014-3022.
Kucher, N. et al., “Percutaneous Catheter Thrombectomy Device for Acute Pulmonary Embolism: In Vitro and in Vivo Testing”, Circulation, Sep. 2005:112:e28-e32.
Kucher, N., “Catheter Interventions in Massive Pulmonary Embolism”, Cardiology Rounds, Mar. 2006 vol. 10, Issue 3, 6 pages.
Kucher, N. et al., “Management of Massive Pulmonary Embolism”, Radiology, Sep. 2005:236:3 852-858.
Kucher, N. et al., “Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism.” Circulation, 2014, 129, pp. 9 pages.
Kuo, W. et al., “Catheter-directed Therapy for the Treatment of Massive Pulmonary Embolism: Systematic Review and Meta-analysis of Modern Techniques”, Journal of Vascular and Interventional Radiology, Nov. 2009:20:1431-1440.
Kuo, W. et al., “Catheter-Directed Embolectomy, Fragmentation, and Thrombolysis for the Treatment of Massive Pulmonary Embolism After Failure of Systemic Thrombolysis”, American College of CHEST Physicians 2008: 134:250-254.
Kuo, W. MD, “Endovascular Therapy for Acute Pulmonary Embolism”, Continuing Medical Education Society of Interventional Radiology (“CME”); Journal of Vascular and Interventional Radiology, Feb. 2012: 23:167-179.
Lee, L. et al., “Massive pulmonary embolism: review of management strategies with a focus on catheter-based techniques”, Expert Rev. Cardiovasc. Ther. 8(6), 863-873 (2010).
Liu, S. et al., “Massive Pulmonary Embolism: Treatment with the Rotarex Thrombectomy System”, Cardiovascular Interventional Radiology; 2011: 34:106-113.
Muller-Hulsbeck, S. et al. “Mechanical Thrombectomy of Major and Massive Pulmonary Embolism with Use of the Amplatz Thrombectomy Device”, Investigative Radiology, Jun. 2001:36:6:317-322.
Reekers, J. et al., “Mechanical Thrombectomy for Early Treatment of Massive Pulmonary Embolism”, CardioVascular and Interventional Radiology, 2003: 26:246-250.
Schmitz-Rode et al., “New Mesh Basket for Percutaneous Removal of Wall-Adherent Thrombi in Dialysis Shunts,” Cardiovasc Intervent Radiol 16:7-10 1993 4 pgs.
Schmitz-Rode et al., “Temporary Pulmonary Stent Placement as Emergency Treatment of Pulmonary Embolism,” Journal of the American College of Cardiology, vol. 48, No. 4, 2006 (5 pgs.).
Schmitz-Rode, T. et al., “Massive Pulmonary Embolism: Percutaneous Emergency Treatment by Pigtail Rotation Catheter”, JACC Journal of the American College of Cardiology, Aug. 2000:36:2:375-380.
Spiotta, A et al., “Evolution of thrombectomy approaches and devices for acute stroke: a technical review.” J NeuroIntervent Surg 2015, 7, pp. 7 pages.
Svilaas, T. et al., “Thrombus Aspiration During Primary Percutaneous Coronary Intervention.” The New England Journal of Medicine, 2008, vol. 358, No. 6, 11 pages.
Tapson, V., “Acute Pulmonary Embolism”, The New England Journal of Medicine, Mar. 6, 2008:358:2037-52.
The Penumbra Pivotal Stroke Trial Investigators, “The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease.” Stroke, 2009, 40: pp. 9 pages.
Truong et al., “Mechanical Thrombectomy of Iliocaval Thrombosis Using a Protective Expandable Sheath,” Cardiovasc Intervent Radiol27-254-258, 2004, 5 pgs.
Turk et al., “ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy.” J NeuroIntervent Surg, vol. 6, 2014, 6 pages.
Uflacker, R., “Interventional Therapy for Pulmonary Embolism”, Journal of Vascular and Interventional Radiology, Feb. 2001: 12:147-164.
Verma, R., MD et al. “Evaluation of a Newly Developed Percutaneous Thrombectomy Basket Device in Sheep With Central Pulmonary Embolisms”, Investigative Radiology, Oct. 2006, 41, 729-734.
International Search Report and Written Opinion for International App. No. PCT/US2015/034987 filed Jun. 9, 2015, Applicant: Inceptus Medical, LLC, dated Sep. 17, 2015, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US2016/067628 filed Dec. 19, 2016, Applicant: Inari Medical, Inc., dated Apr. 10, 2017, 11 pages.
Goldhaber, S. et al. “Percutaneous Mechanical Thrombectomy for Acute Pulmonary Embolism—A Double-Edged Sword,” American College of CHEST Physicians, Aug. 2007, 132:2, 363-372.
Goldhaber, S., “Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy,” Journal of Thrombosis and Haemostasis, 2009: 7 (Suppl. 1): 322-327.
International Search Report and Written Opinion for International App. No. PCT/US2017/029696, Date of Filing: Apr. 26, 2017, Applicant: Inari Medical, Inc., dated Sep. 15, 2017, 19 pages.
International Search Report and Written Opinion for International App. No. PCT/US2016/058536, Date of Filing: Oct. 24, 2016, Applicant: Inari Medical, Inc., dated Mar. 13, 2017, 14 pages.
International Search Report and Written Opinion for International App. No. PCT/US2018/048786, Date of Filing: Aug. 30, 2018, Applicant: Inari Medical, Inc., dated Dec. 13, 2018, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US2018/055780, Date of Filing: Oct. 13, 2018, Applicant: Inceptus Medical LLC., dated Jan. 22, 2019, 8 pages.
International Search Report and Written Opinion for International App. No. PCT/US2019/045794, Date of Filing: Aug. 8, 2019, Applicant: Inari Medical, Inc., dated Nov. 1, 2019, 17 pages.
International Search Report and Written Opinion for International App. No. PCT/US2020/056067, Date of Filing: Oct. 16, 2020; Applicant: Inari Medical, Inc., dated Jan. 22, 2021, 8 pages.
International Search Report and Written Opinion for International App. No. PCT/US2020/055645, Date of Filing: Dec. 17, 2020; Applicant: Inari Medical, Inc., dated Apr. 14, 2021, 12 pages.
Vorwerk, D. MD, et al., “Use of a Temporary Caval Filter to Assist Percutaneous Iliocaval Thrombectomy: Experimental Results.” SCVIR, 1995, 4 pages.
Wikipedia; Embolectomy; retrieved from the internet: https://en.wikipedia.org/wiki/Embolectomy; 4 pgs.; retrieved/printed: Mar. 24, 2016.
O'Sullivan; Thrombolysis versus thrombectomy in acute deep vein thrombosis; Interventional Cardiology; 3(5); pp. 589-596; Oct. 2011.
Capture Vascular Systems; (company website); retrieved from the internet: http://www.capturevascular.com; 3 pgs .; retrieved/printed: Mar. 24, 2016.
Edwards Lifesciences; Fogarty® Occlusion Catheters (product brochure); retrieved from the internet: http://web.archive.org/web/20150228193218/http://www.edwards.com/products/vascular/atraumaticocclusion/pages/occlusioncatheter.aspx; © 2011; 2 pgs.; retrieved/printed: Mar. 24, 2011.
Boston Scientific; Fetch(TM) 2 Aspiration Catheter (product information); retrieved from the internet: http://www.bostonscientific.com/en-US/products/thrombectomy-systems/fetch2-aspiration-catheter.html; 2 pgs.; retrieved/printed: Mar. 24, 2016.
Penumbra, Inc.; Indigo® System (product information); retrieved from the internet: http://www.penumbrainc.com/peripherallpercutaneous-thromboembolectomy/indigo-system; 7 pgs.; retrieved/printed: Mar. 24, 2016.
Youtube; Merci Retrieval System X Series Animation; uploaded Mar. 16, 2009 (product information); posted on May 7, 2009 by SSMDePAUL, time 1:09, retrieved from the internet: https://www.youtube.com/watch?v=MGX7deuFkhc; 3 pgs.; retrieved/printed: Mar. 24, 2016.
Covidien; Solitaire(TM) AS Neurovascular Remodeling Device (product information); retrieved from the internet: http://www.ev3.net/neuro/intl/remodeling-devices/solitaire-ab. htm; © 2015; 2 pgs.; retrieved/printed: Mar. 24, 2016.
International Search Report and Written Opinion for International App. No. PCT/US21/35965, Date of Filing: Jun. 4, 2021, Applicant: Inari Medical, Inc., dated Sep. 28, 2021, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/45072 Date of Filing: Aug. 6, 2021, Applicant: Inari Medical, Inc., dated Jan. 20, 2022, 10 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/58793; Date of Filing: Nov. 10, 2021, Applicant: Inari Medical, Inc., dated Mar. 16, 2022, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/59718; Date of Filing: Nov. 17, 2021, Applicant: Inari Medical, Inc., dated Mar. 22, 2022, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/59735; Date of Filing: Nov. 17, 2021, Applicant: Inari Medical, Inc., dated Mar. 22, 2022, 11 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/60502; Date of Filing: Jan. 11, 2023, Applicant: Inari Medical, Inc., dated May 25, 2023, 9 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/61256; Date of Filing: Jan. 25, 2023, Applicant: Inari Medical, Inc., dated Jun. 7, 2023, 8 pages.
Gross et al., “Dump the pump: manual aspiration thrombectomy (MAT) with a syringe is technically effective, expeditious, and cost-efficient,” J NeuroIntervent Surg, 2018, 4 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/60927; Date of Filing: Jan. 19, 2023, Applicant: Inari Medical, Inc., dated Jul. 20, 2023, 12 pages.
Extended European Search Report issued for EP Application No. 20877370.5, Date of Mailing: Oct. 17, 2023, 11 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/65128; Date of Filing: Mar. 30, 2023, Applicant: Inari Medical, Inc., Date of Mailing: Nov. 14, 2023, 14 pages.
English translation of Japanese Office Action received for JP Application No. 2022-574456, Applicant: Inari Medical, Inc, Date of Mailing: Jan. 23, 2024, 12 pages.
Chinese First Office Action received for CN Application No. 201980067623.1, Applicant: Inari Medical, Inc., Date of Mailing: Jan. 31, 2024, 10 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/73765; Date of Filing: Sep. 8, 2023, Applicant: Inari Medical, Inc., Date of Mailing: Feb. 28, 2024, 7 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/69892; Date of Filing: Jul. 10, 2023, Applicant: Inari Medical, Inc., Date of Mailing: Feb. 29, 2024, 12 pages.
English translation of Japanese Office Action mailed Jan. 19, 2024 for Japanese Application No. 2022- 160947, 8 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/66538; Date of Filing: May 3, 2023, Applicant: Inari Medical, Inc., Date of Mailing: Jan. 4, 2024, 14 pages.

Related Publications (1)

	Number	Date	Country
	20230310137 A1	Oct 2023	US

Provisional Applications (2)

	Number	Date	Country
	62718269	Aug 2018	US
	62718248	Aug 2018	US

Continuations (4)

	Number	Date	Country
Parent	18167757	Feb 2023	US
Child	18329414		US
Parent	17976711	Oct 2022	US
Child	18167757		US
Parent	17865315	Jul 2022	US
Child	17976711		US
Parent	16536185	Aug 2019	US
Child	17865315		US

System for treating embolism and associated devices and methods

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract